

9650 ROCKVILLE PIKE, BETHESDA, MARYLAND 20814-3994

PHONE: 301-530-7178 ♦ FAX: 301-571-1816

Web: [www.aaai.org](http://www.aaai.org)

# THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AAI NEWSLETTER

## Kirschstein to Receive AAI Public Service Award

Ruth L. Kirschstein, M.D., until recently the Acting Director of the National Institutes of Health, will receive AAI's 2002 Public Service Award at a June reception in her honor. AAI President James P. Allison, Ph.D., will present the award to Dr. Kirschstein on June 18th in Bethesda, MD.

Dr. Kirschstein, an AAI member since 1965, was recommended for the award by the AAI Committee on Public Affairs and was approved by the AAI Council. AAI will recognize Kirschstein for "her outstanding scientific and administrative leadership at the National Institutes of Health and for extraordinary commitment to advancing public understanding of and support for biomedical research."

A Brooklyn, N.Y., native, Dr. Kirschstein earned her B.A. from Long Island University and her M.D. from Tulane University. Following a lengthy tenure at the Division of Biologics Standards (now the Center for Biologics



Evaluation and Research, FDA), she was named Director, National Institute of General Medical Sciences in 1974. She also served as Acting Associate Director for Research on Women's Health (1990-1991), Acting Director, NIH (1993), and Deputy Director, NIH (1993-1999).

Again named Acting Director, NIH, on January 1, 2000, Dr. Kirschstein recently resumed her post as Deputy Director, NIH, upon the installation of the newly appointed NIH Director, Dr. Elias Zerhouni. For Dr. Kirschstein's complete bio, visit: [www.nih.gov/about/director/rkbio.htm](http://www.nih.gov/about/director/rkbio.htm).

## INSIDE THIS ISSUE

1. Upon Reflection: Message from the AAI President
2. Focus on Public Affairs
2. Dr. Finn Elected to AAI Council
3. 2002 AAI Election Results
4. AAI Submits Testimony to Congress
4. AAI Supports "Just in Time" Rule Change
5. Grant-Related News
8. Members in the News

## Upon Reflection...

AAI President James P. Allison, Ph.D.

As I look back on my year as President, it is undeniable that we have been confronted with profound changes in our personal and professional lives -- the most significant being those brought about by the tragic events of last September 11. But I think we've emerged stronger for them with a clearer sense of purpose and gratitude.



This year also brought several challenges to the AAI. The events of September required that we redirect our public affairs efforts. Previously, efforts of the AAI Public Affairs Committee and AAI members had been directed largely to issues of funding of basic research, including supporting the effort to double funding for the NIH over a five-year period (which seems to be on track for completion this year). However, in the period immediately following September 11, as Congressional attention appropriately turned toward fighting and funding a war, safeguarding our citizens, and responding to the new reality of bioterrorism (as evidenced by the anthrax attacks), AAI focused more on several key regulatory issues. These included successfully fighting the proposal to include research rats, mice, and birds under the protections of the Animal Welfare Act (see page 2; Focus on Public Affairs). By this spring, AAI's attention returned again to NIH funding, particularly the NIAID budget, to which the President proposed an amazing 52% increase (at this writing, Congress is currently poised to adopt this increase). Much of this funding will go towards basic research as it relates to biodefense in the war against

see *iUpon Reflectioni*, page 3

11. *In Memoriam*: Morten Simonsen
  11. 2002-'03 High School Teachers Program Set
  12. 2002 AAI Awardees
  14. AAI Welcomes New Members
  19. Meeting Announcements
  22. AAI Membership Applications
  24. 2003 AAI Award Applications
- Back cover: Websites of Interest**

THE AMERICAN  
ASSOCIATION OF  
IMMUNOLOGISTS

9650 Rockville Pike  
Bethesda, Maryland  
20814-3994  
Tel: 301-530-7178  
Fax: 301-571-1816  
Email: infoaai@aai.faseb.org  
AAI Homepage:  
[www.aai.org](http://www.aai.org)

Member Services  
Tel: 301-530-7195  
Email: members@aai.faseb.org

*The Journal of Immunology*  
Tel: 301-530-7197

## Council

### President

James P. Allison, PhD

### Vice President

Paul W. Kincade, PhD

### Past President

Philippa Marrack, PhD

### Secretary-Treasurer

J. Donald Capra, MD

### Councillors

Laurie H. Glimcher, MD  
Susan L. Swain, PhD  
Paul M. Allen, PhD  
Lewis L. Lanier, PhD

### Executive Director

M. Michele Hogan, PhD

### Staff

Director of Public Policy and  
Government Affairs  
Lauren G. Gross  
[lgross@aai.faseb.org](mailto:lgross@aai.faseb.org)

### Director of Finance

Jan C. Massey, C.P.A.  
[jmassey@aai.faseb.org](mailto:jmassey@aai.faseb.org)

### Executive Assistant

Michael W. Cuddy  
[mwcuddy@aai.faseb.org](mailto:mwcuddy@aai.faseb.org)

### Membership Services

Lisa McFadden  
[members@aai.faseb.org](mailto:members@aai.faseb.org)

### Senior Administrative Assistant

Pamela Booth  
[pbooth@aai.faseb.org](mailto:pbooth@aai.faseb.org)

### Accounting Assistant

Vivian Chin  
[vchin@aai.faseb.org](mailto:vchin@aai.faseb.org)

### Director of Publications (The JI)

Ann M. Link  
[alink@ji.faseb.org](mailto:alink@ji.faseb.org)

## FOCUS ON PUBLIC AFFAIRS

It has been a busy and extraordinary period for biomedical research over the last several months. We continue to receive tremendous support from both Congress and the Bush Administration on a wide range of issues, including funding, reflecting in part a continuing bipartisan appreciation of the value and promise of biomedical research. Another important reason for this strong support is that scientists - and in particular, immunologists, microbiologists, and infectious disease specialists - have become the next "front" in the war against terrorism (see below).

AAI's reaction to the President's budget and recommendations for FY 2003 are detailed in testimony submitted to the House Appropriations Subcommittee on Labor, Health and Human Services, and Education by Committee on Public Affairs Chair Jeffrey A. Frelinger, Ph.D., on May 8, 2002 (similar testimony was submitted to the Senate in April). Dr. Frelinger's testimony appears on page 4.

### Appropriations for FY 2003

Both the Senate and House of Representatives have been holding hearings on the President's FY 2003 budget. At this writing, both the House and the Senate Appropriations Subcommittees on Labor, Health and Human Services, and Education, appear poised to approve the 5<sup>th</sup> and final year of doubling the NIH budget. If this takes place as expected, the NIH budget would increase \$3.9 billion in FY 2003, resulting in a total budget of \$27.3 billion. According to hearing testimony submitted by then NIH Acting Director Ruth L. Kirschstein, M.D., this budget level "would fund a total of 9,854 new, competing research grants or a total of 38,038 awards, the highest annual total ever. Intramural research increases by 15% over the FY2002 estimate, with most Institutes and Centers increasing by 9 percent, while the NIAID and the NCI increase by 52 percent and 11 percent respectively." A supplemental appropriations bill is also working its way through Congress and will likely include additional funds for what is now being called "biodefense research."

### Bioterrorism/"Biodefense" research

Approximately \$1.7 billion of the proposed \$3.9 billion funding increase for FY 2003 will go to the NIAID for "biodefense". The NIAID recently released two publications outlining this new imperative in biomedical research: the *NIAID Strategic Plan for Biodefense Research* (Feb. 2002 -- see <http://www.niaid.nih.gov/dmid/pdf/strategic.pdf>) and the *NIAID Biodefense Research Agenda for CDC Category A Agents* (Feb. 2002 -- see <http://www.niaid.nih.gov/dmid/pdf/biotresearchagenda.pdf>).

see *iFocus*, p. 6

## Olivera (Olja) J. Finn, Ph.D., Elected to AAI Council

Dr. Olja Finn, Professor and Chair, Department of Immunology, University of Pittsburgh School of Medicine, and Leader, Immunology Program, University of Pittsburgh Cancer Institute, has been elected as the newest member of the AAI Council. Dr. Finn's term as councillor will run from July 1, 2002 - June 30, 2006. Dr Finn received her Ph.D. in Immunology/Virology from Stanford University in 1980. She has served on the AAI Program

Committee (1991-1994) and Committee on Public Affairs (1996-1999; 2001-2002) and as a reviewer for *The Journal of Immunology*. In addition, she has chaired AAI block symposia (1994, 1995) and served as invited speaker at AAI major symposia (1999, 2002) and the Presidential Symposium (2002). Dr. Finn has been an AAI member since 1983.



## 2002 AAI Election Results

### President

Paul W. Kincade, Ph.D.

### Vice President

Laurie H. Glimcher, M.D.

### Councillor

Olivera (Olja) J. Finn, Ph.D.

### Awards Committee

Linda A. Sherman, Ph.D.

### Finance Committee

Ann Marshak-Rothstein, Ph.D.

### Program Committee

Carl F. Ware, Ph.D.

Pamela Fink, Ph.D.

### Publications Committee

Janice S. Blum, Ph.D.

### Nominating Committee

Max D. Cooper, M.D. (Chair)

Jane R. Parnes, M.D.

Christine A. Biron, Ph.D.

Mitchell Kronenberg, Ph.D.

Yvonne Paterson, Ph.D.

Newly elected members of Council and Committees will assume their positions on July 1, 2002. The length of their terms is set forth in the AAI bylaws.

By accepting a place on the ballot, all 2002 candidates demonstrated their willingness to serve the association, and AAI extends thanks for this commitment.

AAI also salutes the incumbent members of Council and Committees whose terms expire on June 30, 2002. Their active participation in advancing the interests of AAI and its members is recognized with appreciation.

### AAI Council and Committees – Expiring Terms, 2002

COUNCIL -- Philippa **Marrack**, Ph.D., Past President

COMMITTEES -- *Awards*: Richard W. **Dutton**, Ph.D.; Sherie L. **Morrison**, Ph.D.; *Clinical Immunology*: Megan **Sykes**, M.D.; Dale T. **Umetsu**, M.D., Ph.D.; *Education*: Leslie J. **Berg**, Ph.D.; Marc K. **Jenkins**, Ph.D.; Ronald H. **Stevens**, Ph.D.; *Finance*: Gail A. **Bishop**, Ph.D.; Jeffrey A. **Bluestone**, Ph.D.; *Membership*: Ellen **Puré**, Ph.D.; Joan **Stein-Streilein**, Ph.D.; *Minority Affairs*: John F. **Finerty**, Ph.D. (Chair); Rafael **Fernandez-Botran**, Ph.D.; Donald G. **Payan**, M.D.; *Nominating*: Nancy H. **Ruddle**, Ph.D. (Chair); Rafi **Ahmed**, Ph.D.; Ann J. **Feeney**, Ph.D.; Brigitte T. **Huber**, Ph.D.; Kenneth L. **Rock**, M.D.; *Program*: Jason G. **Cyster**, D. Phil.; Gary A. **Koretzky**, M.D., Ph.D.; Pamela S. **Ohashi**, Ph.D.; David H. **Raulet**, Ph.D.; *Publications*: James **Forman**, DMD, Ph.D. (Chair); John W. **Kappler**, Ph.D.; Sherie L. **Morrison**, Ph.D.; *Public Affairs*: Judith A. **Kapp**, Ph.D.; Raymond M. **Welsh**, Ph.D.; *Status of Women*: Etty **Benveniste**, Ph.D.; Olivia M. **Martinez**, Ph.D.; Jill **Suttles**, Ph.D.; *Veterinary Immunology*: Doug **Antczak**, VMD, Ph.D. (Chair); Harm **HogenEsch**, DVM, Ph.D.; Mariangela **Segre**, D.Sc.

**Thank You!**

## Upon Reflection... (cont'd from p. 1)

terrorism, including basic research in the pathogenesis of and immune response to infectious diseases, new strategies in the development of vaccines, and treatment of emerging and re-emerging diseases. Our challenge for the near future will be to mobilize our membership to turn their time and talents toward addressing these urgent national priorities, remembering that progress in biodefense will advance critically important public health needs as well as knowledge crucial to basic immunological science.

Another major event this past year was the appointment of a new Editor-in-Chief for *The Journal of Immunology*. The AAI Council is pleased that Dr. Robert R. Rich will assume this role beginning full-time in January, 2003. This transition will occur after a period of remarkable leadership by our current Editor-in-Chief, Dr. Frank W. Fitch. Frank worked tirelessly over the past five years to enhance the reputation of *The JI* as a responsive society journal. He sought ways to shorten the review and publication times, deliver content rapidly online, and listen to the needs, frustrations and constructive criticism from authors, editors, reviewers and the readership. For his personal investment in the AAI and *The JI*, he was awarded the 2002 AAI Distinguished Service Award at the recent annual meeting.

AAI held another tremendously successful annual meeting in New Orleans with six other EB societies. A total of 6,000 abstracts submitted to this meeting (1300 presented in AAI sessions) and over 14,000 registered scientists created a high energy event. All of AAI's Plenary and Major Symposia were well attended and over 50 Block Symposia gave cutting edge presentations. AAI's awards program continues to grow and over 60 scientists were honored in various ways including lectures and travel awards. And once again the AAI Gala held on to its reputation for being the best party in town.

And finally, our membership reached an all-time high of over 6400 members at the close of 2001. I think this reflects the increasingly important role that AAI plays in the professional lives of its members. From its top-rated journal to its dynamic public affairs program to its captivating annual meetings, AAI enters its 90<sup>th</sup> year serving its members ably and well. I have enjoyed serving as President and thank my colleagues on the Council and AAI committees, as well as the AAI staff, for all their hard work.

---

AAI is interested in the achievements of its members. If you have recently received an honor or award or have been elected to an honorary society or board, please let us know:

MEMBERS IN THE NEWS  
AMERICAN ASSOCIATION OF IMMUNOLOGISTS (AAI)  
9650 ROCKVILLE PIKE  
BETHESDA, MD 20814  
EMAIL: MWCUDDY@AAI.FASEB.ORG

## AAI Submits Testimony to Congress on FY 2003 NIH Budget

AAI Committee on Public Affairs Chair Jeffrey A. Frelinger, Ph.D., submitted the following testimony on behalf of AAI to the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, regarding the President's FY 2003 budget for the National Institutes of Health. Frelinger submitted similar testimony to the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies in April.

**Statement of Jeffrey A. Frelinger, Ph.D.**  
**Chair of the Committee on Public Affairs of the American Association of Immunologists**  
**to the**  
**House Appropriations Subcommittee on Labor, Health and Human Services,**  
**Education and Related Agencies**  
**Regarding the FY 2003 Budget for the National Institutes of Health**  
**May 8, 2002**

The American Association of Immunologists (AAI), a non-profit professional association of more than 6,000 research scientists and physicians dedicated to understanding the immune system - resulting in the prevention, treatment, and cure of disease - appreciates this opportunity to express its views on the President's FY 2003 Budget Request for the National Institutes of Health (NIH). Before we do, we would like to express our deep appreciation to the members of this subcommittee and to its chairman, Mr. Regula, for your extraordinary support for biomedical research and the National Institutes of Health. We are grateful for your continuing dedication to government sponsored biomedical research and the scientists this funding supports.

### Immunology

The study of immunology spans a wide range of diseases and conditions which affect the lives of every American. Our scientists use grants from the NIH, and in particular from the National Institute of Allergy and Infectious Diseases (NIAID),<sup>1</sup> to understand the workings of the immune system. This information allows for delineating the causes of disease and discovering treatments and potential cures. Immunologists are currently engaged in many such activities, including:

- developing effective vaccines against HIV/AIDS, influenza, and other infectious and chronic diseases;
- discovering new defenses against emerging and re-emerging bacteria (such as tuberculosis) and drug resistant bacteria (including antibiotic-resistance);
- regulating autoimmune diseases such as diabetes, myasthenia gravis, and lupus;
- discovering the causes of cancer and promising new treatments;
- developing treatments to prevent the rejection of transplanted organs and bone marrow.

*see iTestimonyi, p. 16*

## AAI Supports "Just in Time" Rule Change

AAI recently submitted comments to the National Institutes of Health (NIH) regarding a proposed rule change to the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals. This change would permit institutions with PHS Animal Welfare Assurances to submit verification of Institutional Animal Care and Use Committee (IACUC) approval for competing applications to NIH subsequent to peer review but prior to the award. In his letter to Anthony Demsey, Ph.D., Senior Advisor for Policy in the NIH Office of Extramural Research, AAI Committee on Public Affairs Chair Jeffrey A. Frelinger, Ph.D., explained that "[t]his concept, sometimes referred to as "just-in-time", would greatly reduce the regulatory burden on applicants and the applicant organizations by removing the need to review proposals that are not likely to be approved for funding by NIH" and would likely "enhance the quality of the review for the applications that are likely to be funded...." Frelinger's letter appears here, at right.



## Grant-Related News

### Challenge and Opportunity Converge As NIAID Biodefense Initiatives Take Shape

NIAID is inviting grant applications consistent with its strategic plan for support of biodefense research. The NIAID Advisory Council recently gave pre-approval to 23 research concepts involving basic research on emerging infectious diseases, including those with the potential to be used as biological weapons, and applied research leading to new products for protecting the public from disease.

Representing NIAID's biodefense priority areas -- including biology of the microbe; host response; vaccines; therapeutics; diagnostics; and research resources -- the concepts underlie current and future funding initiatives to appear on the Institute's Biodefense Research website, at <http://www.niaid.nih.gov/dmid/bioterrorism>. Site links include lists of NIAID's Category A, B, & C priority pathogens and high priority products for biodefense.

### Abbott Launches Scholar Award in Rheumatology

Earlier this year, Abbott Laboratories announced the establishment of the Abbott Scholar Award in Rheumatology Research. The mentored research award is designed to help develop future leaders in academic rheumatology by providing funding and support to physicians in the early stages of their career in rheumatology. The award will support basic and translational research related to rheumatic diseases, including epidemiology, health services research in arthritis and related autoimmune disease, and innovative clinical research.

The program seeks physicians of high potential who demonstrate commitment to a career in academic rheumatology, a plan for career development, and commitment from their mentor and institution. In addition, candidates must commit at least 80 percent of their time to research and training. The mentors identified by the candidates must have an established record of successful research, current research funding, and a record of success in mentoring the career development of past trainees. An independent advisory panel of 12 clinical and research experts in rheumatology, working with a large panel of respected leaders in academic rheumatology, will review applications to select candidates for the Abbott Scholar Award.

The summer grant cycle will accept new applications through September 15, 2002. For more information, visit [www.abbotscholar.com](http://www.abbotscholar.com) or phone (201) 553-8820.

### AAAS's WISC Program Continues

The American Association for the Advancement of Science (AAAS) recently announced the second round of applications for the 2002-2003 Women's International Science Collaboration (WISC) Program. Supported by the U.S. National Science Foundation (NSF), this program aims to increase the participa-

*see iWISC Program, next column*

### AAI Council Approves Grant Review Program for New Investigators

The AAI Council recently approved a proposal by Committee on Public Affairs member Andy Hurwitz, Ph.D., to establish a program within AAI to provide grant review assistance to new investigators as they embark on an independent immunology research career. The "Grant Review for Immunologists Program" ("GRIP") is intended to assist new principal investigators who would benefit from expertise in their proposed area of research that may not be available at the new PI's own institution. While GRIP is not designed to replace internal mentoring, it will serve as a referral resource to match newly appointed PIs (who may not have colleagues with the appropriate expertise in their area of specialization) with established PIs that have significant, successful grant writing careers.

Together with a small subcommittee, a program coordinator to be appointed by Council will review an outline or NIH-style abstract submitted by the new PI and attempt a match with an established PI who has expertise in the proposed area of research and who has agreed to participate in the program.

GRIP program details, including information on how members can apply to participate, will be forthcoming in future newsletters and on the AAI website: [www.aai.faseb.org](http://www.aai.faseb.org)

### ...WISC Program (cont'd)

tion of women in international scientific research through travel awards to locations around the world, fostering research partnerships between U.S. scientists and colleagues in other countries.

Applicants must be female, have a female co-principal investigator, or propose a partnership with a female researcher in another country. Potential applicants should review the program guidelines (see URL below) or consult an AAAS administrator for details. Applicants must have a Ph.D. or equivalent research experience. Graduate students (Ph.D. candidates) are eligible if they will be conducting research in an established Ph.D. program in the U.S. For further information on fields eligible for funding, please visit the NSF website at <http://www.nsf.gov> or contact one of the AAAS administrators below.

The next application deadline is July 15, 2002. For information, visit <http://www.aaas.org/international/wiscnew.shtml> or contact the appropriate AAAS administrator:

\* *Central and Eastern Europe, Newly Independent States (NIS) of the former Soviet Union:* Karen Grill, [kgrill@aaas.org](mailto:kgrill@aaas.org), (202) 326-7027

\* *East Asia and Pacific:* Suteera Nagavajara, [snagavaj@aaas.org](mailto:snagavaj@aaas.org), (202) 326-6496

\* *Africa, Middle East, Near East, and South Asia:* Alan Bornbusch, [abornbus@aaas.org](mailto:abornbus@aaas.org), (202) 326-6651

\* *Americas and Caribbean:* Marina Ratchford, [ratchfo@aaas.org](mailto:ratchfo@aaas.org), (202) 326-6490

*for more Grant Related News, see Fulbright Award, p. 13*

## FOCUS (cont'd from p. 2)

The following description is from the *Research Agenda's* Introduction: *iThis...Agenda supplements the strategic plan and articulates the goals for research on anthrax, smallpox, plague, botulism, tularemia, and viral hemorrhagic fevers. The research agenda focuses on the need for basic research on the biology of the microbe, the host response, and basic and applied research aimed at the development of diagnostics, therapeutics, and vaccines against these agents. In addition, the agenda addresses the research resources, facilities, and scientific manpower needed to conduct both basic and applied research on these agents.i*

The NIAID Director, Dr. Anthony Fauci, addressed this research agenda at a symposium entitled "Bioterrorism: New Threats Facing the Nation, New Challenges for the Scientific Community" at the EB meeting in New Orleans on Sunday, April 21, 2002. AAI is working with NIAID to help alert our membership to new research opportunities in the biodefense area.

### RM&S Budget

The President's budget contains excellent news regarding the Research Management and Support (RM&S) budget, which increases by 17% in FY 2003. All Institutes and Centers except NCI and NIAID increase by 9%. While it is unclear precisely the level of additional RM&S funds NCI and the NIAID will receive, it is clear each will receive considerably more than 9%.

### Post-doctoral stipends

The President's budget fails to implement the NIH plan to raise post-doctoral stipends, a plan which AAI had encouraged and still supports. NIH had issued a plan to raise post-doc (NRSA) stipends 10% per year for 5 years to reach a more livable minimum annual salary of \$45,000 for entry level postdocs. After one year of raising the stipend by 10%, the President's FY 2003 budget (and thus the NIH budget) includes a stipend increase of only 4%. AAI has urged Congress in our recently-submitted testimony to support the NIH plan by resuming the increases that NIH had planned.

### Extramural Salary Cap

Another problem with the President's FY 2003 budget is a provision which would roll back the current salary cap for extramural researchers at NIH from \$161,200 (Executive Level I) to \$145,100 (Executive Level II). This same provision was in last year's House version of the FY 2002 Labor/HHS appropriations bill, but was excluded from the final conference agreement and therefore did not become law. Last year, AAI opposed this provision and contacted all conferees to express our opposition; we have already expressed our opposition to this year's effort to roll back the salary cap through Congressional testimony and intend to continue addressing this problem.

### Rats, Mice & Birds

In addition to our success on the NIH doubling campaign, we are celebrating the successful conclusion of our effort to exclude rats, mice, and birds from the Animal Welfare Act. Earlier this Congressional session, Senator Jesse Helms (R-NC) offered an amendment to The Farm Security and Rural Investment Act of 2002 ("the Farm bill") to exclude permanently research rats, mice, and birds from the Animal Welfare Act. The Farm bill was a large, comprehensive, and highly contentious bill, with the rats/mice/birds section one of many smaller controversies embroiled in it. After many months of uncertainty as to its fate, the Farm bill was recently passed by both the House and Senate, and was signed into law by President Bush in early May. The National Association for Biomedical Research (NABR), with which AAI worked on this issue, deserves great credit for its excellent leadership and this successful outcome.

### "Puppy Protection Act"

An earlier version of the Farm bill also contained the Puppy Protection Act, which was introduced by Senator Rick Santorum (R-PA). The bill was intended to improve conditions among commercial breeders who provide dogs as pets. According to the American Physiological Association (APS), however, the amendment would affect any institution that is breeding or selling dogs, including some research facilities and pharmaceutical companies, and would allow the imposition of new breeding limitations through the development of "engineering standards" without regard to the professional judgment of the attending veterinarian ("performance-based standards"). Because of these and other problems with the bill, AAI wrote to Sen. Santorum, Senator Tom Harkin (D-IA), and Senator Richard Durbin (D-IL) to express our concerns and to ask that the amendment be modified. While the amendment was modified somewhat, we remained concerned enough about its language to support efforts to remove the amendment from the bill. It was not part of the final Farm bill which became law.

### New NIH Director

In March, President Bush announced his intent to nominate radiologist Elias Zerhouni, M.D., to be Director of NIH. Dr. Zerhouni was most recently the Executive Vice Dean of the Johns Hopkins University School of Medicine, Chairman of the Russell H. Morgan Department of Radiology and Radiological Science at Johns Hopkins, and Professor of Radiology and Biomedical Engineering. He has also served as Vice Dean for Research at The Johns Hopkins University School of Medicine. The White House emphasized

## FOCUS *(cont'd from p. 6)*

Zerhouni's "strong scientific research background, including work on NIH-sponsored research; [e]xperience in running a large medical research organization; and [l]eadership on the cutting edge of medical technology."

Dr. Zerhouni's confirmation hearing was held by the Senate Health, Education, Labor and Pensions Committee in April. He was extremely well-received by the committee, which voted the following day to report his nomination favorably to the full Senate. Later that week, the Senate confirmed Dr. Zerhouni's nomination; Dr. Zerhouni was sworn in and began serving as NIH Director on May 20, 2002. AAI's President, James P. Allison, Ph.D., sent Dr. Zerhouni a letter of congratulations, introducing AAI to him and offering our best wishes and assistance.

### Human Cloning Legislation

Senate debate on anti-human cloning legislation introduced by Senator Sam Brownback (R-KS), originally scheduled for March, is now likely to take place in June. This bill would prohibit and criminalize "therapeutic cloning", i.e, somatic cell nuclear transfer. Most scientific, research, and academic organizations oppose this legislation, and are supporting instead a compromise bill recently introduced by Senators Arlen Specter (R-PA), Dianne Feinstein (D-CA), Orrin Hatch (R-UT), Ted Kennedy (D-MA), Tom Harkin (R-IA), Barbara Boxer (D-CA), Richard Durbin (D-IL), Zell Miller (D-GA), Jon Corzine (D-NJ), Barbara Mikulski (D-MD), Hillary Rodham Clinton (D-NY), and Strom Thurmond (R-SC). S. 2439, the "Human Cloning Prohibition Act of 2002", would prohibit human cloning but allow somatic cell nuclear transfer research to continue. AAI Committee on Public Affairs Chair Jeffrey A. Frelinger, Ph.D., recently wrote to the key sponsors of this legislation to express AAI's support. Excerpts from that letter follow.

*AAI opposes human reproductive cloning as it is unsafe, unethical and unsupported by the current state of scientific knowledge. We appreciate that S.2439 makes clear that such cloning would not be permitted. We do, however, strongly support permitting scientists to pursue research involving therapeutic cloning, also known as somatic cell nuclear transfer, and believe that this technique holds great promise for understanding, treating, and curing many diseases and disorders. For example, as immunologists we are particularly hopeful that further research on somatic cell nuclear transfer may advance our understanding of - and ability to prevent - immune rejection, which hinders the success of current therapies for both bone marrow and solid organ transplantation....AAI recognizes the significant ethical and moral concerns that are raised by opponents of this research but believes that your legislation addresses those issues by providing appropriate safeguards.*

### Come to D.C.!

AAI continues to work on the issues described above and on many others, and to communicate with elected and appointed officials to address the needs and concerns of our membership. We welcome your active participation - I would be delighted to take you to Capitol Hill to meet with your Senator and Congressperson to help educate them about the important work that you do. Please email me at [lgross@aai.faseb.org](mailto:lgross@aai.faseb.org) if you would like to become involved with our Public Affairs efforts or if you would like to visit "the Hill" the next time you are in Washington.

*-- Lauren G. Gross, Director of Public Policy and Government Affairs*



*photo by Richard Grant, courtesy of Denver Metro Convention & Visitors Bureau*

## Members in the News

### Susan Swain Named NY State Senate Woman of Distinction

AAI Councillor Susan Swain, Ph.D. (AAI '77), director of the Trudeau Institute in Saranac Lake, NY, has been named a New York State Senate Woman of Distinction for 2002. She was nominated by NY State Senator Ronald B. Stafford, in part for the success and significant growth of the Trudeau Institute under her leadership.



The Trudeau Institute is a not-for-profit biomedical research center which traces its origins to the Trudeau Sanitarium and Saranac Laboratory for the Study of Tuberculosis, founded in 1884 by Dr. Edward Livingston Trudeau. Today, Dr. Swain and colleagues at the world-renowned institute study the immune system and explore strategies to combat cancer, tuberculosis, AIDS, and other life-threatening diseases through the development of effective vaccines.

Dr. Swain earned her B.A. from Oberlin College and Ph.D. in Immunology from Harvard Medical School. She has authored over 170 leading journal articles, is a sought-after scientific speaker, and has served on the editorial boards of several publications, including *The Journal of Immunology*. Recipient of the NIH Merit Award in 1996, Dr. Swain was elected to the AAI Council in 1999.

New York's Women of Distinction program was created in 1998 to recognize New York women who exemplify personal excellence or whose professional achievements or acts of courage, selflessness, integrity, or perseverance serve as an example to all New Yorkers. Dr. Swain was honored at a May 21, 2002, reception in the state capital of Albany, where her photograph and biography were on display in a special public exhibit at the Legislative Office Building. In accepting the honor, Dr. Swain saluted her nominator, Sen. Stafford, for his community support and first-hand recognition of the need for fundamental research.

### Diaz, Lewis, Liu, and Locksley Are New NIAID Council Members

In December 2001, four AAI members were among five new appointees to the NIAID Council (formally, the National Advisory Allergy and Infectious Diseases Council). Luis A. Diaz, M.D. (AAI '80), Dorothy E. Lewis, Ph.D. (AAI '85), Margaret Ann Liu, M.D. (AAI '93), and Richard M. Locksley, M.D. (AAI '88) will serve terms ending in 2005, and are profiled on the NIAID Council News website (<http://www.niaid.nih.gov/ncn/council/bios.htm>):


\* *Luis Diaz, M.D.*, is professor and chairman of the department of dermatology at the University of North Carolina at Chapel Hill. Dr. Diaz's research is in cutaneous autoimmunity. He has made important contributions in autoantibody-mediated disease in pemphigus and pemphigoid. Additionally, he is interested in medical education and patient care.



\* *Dorothy E. Lewis, Ph.D.*, is professor of immunology at Baylor College of Medicine in Houston, Texas, and director of the department's graduate program, the Core Flow Cytometry Facility, and the Immunology Core for the Center for AIDS Research. Dr. Lewis's research focuses on the immune response to HIV and mechanisms

responsible for failure to generate sufficient memory cells in most infected people. She is also an expert in flow cytometric applications and serves as an advisor to the Los Alamos National Flow Facility.

\* *Margaret A. Liu, M.D.*, is senior advisor in vaccinology at the Bill & Melinda Gates Foundation and vice-chairman of Transgene, S.A. She is also chairperson of the scientific advisory group of the International Vaccine Institute. A pioneer in the field of DNA vaccines, Dr. Liu's research in immunology includes the generation of cellular immunity to viruses and cancer.



\* *Richard M. Locksley, M.D.*, is chief of infectious diseases, professor of medicine, and investigator in the Howard Hughes Medical Institute at the University of California San Francisco. He has served as a member and chair of study sections for NIAID and WHO and chairs the US/Japan Immunology Board for the NIH.

Dr. Locksley's research investigates mechanisms by which T cells acquire their distinct effector functions and the dysregulation of effector function that occurs in various infectious and inflammatory diseases.

see *iNIAID Councili*, page 9

## NIAID Council (*cont'd*)

The NIAID Council is responsible for advising, consulting with, and making recommendations to the Director, NIH, on NIAID research activities and functions. It provides final review, for scientific merit and program priority, of all applications for research grants, training grants, and career development awards assigned to NIAID. It also reviews and provides clearance for concepts, originating in the scientific community and Congress, for potential NIAID research initiatives.

The Council's 18 voting members include 12 health or science experts, who offer technical expertise on the needs of the research community, and six lay members, who contribute the perspective of those affected by diseases targeted by NIAID-supported research. Each new member serves on one of three NIAID Council subcommittees, including Allergy, Immunology, and Transplantation (Drs. Diaz and Locksley); AIDS (Dr. Lewis); and Microbiology and Infections Diseases (Dr. Liu).

Other NIAID Council members include:

**Anthony S. Fauci, M.D.** (Chair), Director, NIAID; **William Ellis Bertrand, Ph.D.**, Tulane University; **H. Kim Bottomly, Ph.D.**, Yale University; **Charlotte Webb Collins, J.D.**, Powell, Goldstein, Frazier and Murphy, Washington, DC; **Raif Salim Geha, M.D.**, Harvard Medical School; **Ellen Heller Goldberg, Ph.D.**, Santa Fe Institute, Santa Fe, NM; **Barton F. Haynes, M.D.**, Duke University; **Jay Brooks Jackson, M.D.**, Johns Hopkins Medical Institutions; **William R. Jacobs, Ph.D.**, HHMI - Albert Einstein College of Medicine; **Fred Jones, Jr., Ph.D.**, Meharry Medical College; **Gerald Lee Mandell, M.D.**, University of Virginia; **John Charles Martin, Ph.D.**, Gilead Sciences, Inc., Foster City, CA; **Marie M. Saint Cyr**, Iris House, Inc., New York, NY; **Magdalene Y. So, Ph.D.**, Oregon Health Sciences University; **Thelma King Thiel, R.N.**, Hepatitis Foundation International, Cedar Grove, NJ; **Lawrence R. Deyton, M.D.** (*ex officio*), Director, AIDS Service, U.S. Department of Veterans Affairs; **James M. Hughes, M.D.** (*ex officio*), Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention; **Tommy G. Thompson** (*ex officio*), Secretary, U.S. Department of Health and Human Services; Executive Secretary: **John J. McGowan, Ph.D.**, Director, Division of Extramural Activities, NIAID.

## Seven AAI Members Elected to National Academy of Sciences

The National Academy of Sciences recently announced its 2002 election of 72 new members and foreign associates, including seven AAI members. Six individuals were elected to regular membership and one as a foreign associate member (nonvoting member of the Academy, with citizenship outside the United States.) Members and associates are selected in recognition of distinguished and continuing achievements in original research.

AAI members elected to NAS membership this year are:

### **Harvey Cantor, M.D.** (AAI '75)

Professor and Chair, Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute/Harvard Medical School

### **Francis V. Chisari, M.D.** (AAI '75)

Professor, Department of Molecular and Experimental Medicine and Director, General Clinical Research Center, Scripps Research Institute

### **Richard A. Flavell, Ph.D.** (AAI '90)

Professor and Chairman, Department of Immunobiology, Yale University School of Medicine and Investigator, Howard Hughes Medical Institute

### **Laurie H. Glimcher, M.D.** (AAI '83)

Professor of Immunology and Medicine, Department of Immunology and Infectious Diseases, Harvard School of Public Health and Medicine

### **Morris Goodman, Ph.D.** (AAI '53)

Professor, Department of Anatomy and Cell Biology, Wayne State University School of Medicine

### **Patricia G. Spear, Ph.D.** (AAI '97)

Professor, Department of Microbiology and Immunology, Northwestern University Medical School

The following AAI member was elected as a foreign associate member:

### **Tak Wah Mak, M.D., Ph.D.** (AAI '88)

Senior Staff Scientist, Department of Medical Biophysics and Immunology, Ontario Cancer Institute

Election to membership in the National Academy of Sciences is considered one of the highest honors that can be accorded a U.S. scientist or engineer. The 2002 election brings the total number of active NAS members to 1,907 and the number of foreign associates to 330.

The National Academy of Sciences is a private organization of scientists and engineers dedicated to the furtherance of science and its use for the general welfare. It was established in 1863 by a congressional act of incorporation signed by Abraham Lincoln, calling on the Academy to act as an official adviser to the federal government, upon request, in any matter of science or technology.

AAI president James P. Allison, Ph.D., wrote to AAI's NAS electees on May 1, 2002, congratulating them on the honor. Noting that those elected to NAS membership may include mathematicians and scientists from across the physical and biological sciences spectrum, Dr. Allison called AAI's representation in the 2002 NAS class "remarkable".

AAI's newly elected NAS members join 52 immunologists previously elected to the Academy:

**Allison**, James P.; **Alt**, Frederick W.; **Amos**, D. Bernard; **Austen**, K. Frank; **Benacerraf**, Baruj; **Bloom**, Barry R.; **Boyse\***, Edward A.; **Chase**, Merrill W.; **Cooper**, Max D.; **Crabtree**, Gerald R.; **Cresswell**, Peter; **Davis**, Mark M.; **Dixon**, Frank J.; **Doherty**, Peter; **Eisen**, Herman N.; **Fauci**, Anthony S.; **Fearon**, Douglas T.; **Good**, Robert A.; **Gowans**, James; **Grey**, Howard M.; **Honjo**, Tasuku; **Hood**, Leroy; **Ishizaka**, Kimishige; **Janeway**, Charles A., Jr.; **Kappler**, John W.; **Kishimoto**, Tadamitsu; (\* = *not an AAI member*)

*see National Academy, p. 13*

## Bo Dupont, John Hansen Are ASBMT Lifetime Achievement Awardees

AAI members Bo Dupont, M.D., D. Sc. (AAI '75) and John Hansen, M.D. (AAI '77) were recently named co-recipients of the American Society for Blood and Marrow Transplantation (ASBMT) Lifetime Achievement Award. The award annually recognizes individuals who have made continuing contributions to the field of blood and marrow transplantation, either in basic biology or clinical applications.

Dupont and Hansen, pioneers in blood and marrow transplantation, have collaborated for three decades on the genetics of stem cell transplantation and the development of more powerful and precise methods for matching patients and donors. Their discoveries have enhanced understanding of requirements for matching for major histocompatibility alleles, thereby improving the safety and success of transplantation.



**Bo Dupont, M.D., D.Sc.**

Dr. Dupont, a member of the Memorial Sloan-Kettering Cancer Center and professor of immunology at Cornell University, Weill Graduate School of Medical Sciences in New York, began working on compatibility questions in 1971 at Rigshospitalet, University of Copenhagen, Denmark. Dr. Hansen, professor of medicine at the University of Washington and a member of the Fred Hutchinson Cancer Research Center in Seattle, initiated his research on human immunogenetics at the University of Minnesota in Minneapolis in 1972. Their early studies led to the first successful stem cell transplants using unrelated HLA-matched donors.

They were driving forces during the 1980s in the establishment of the National Marrow Donor Program, a registry that matches unrelated blood stem cell donors with patients who do not have an HLA-matched donor in their family. Dr. Dupont helped bring about the initial successful partially matched transplants and, with Dr. Hansen, developed strategies for identifying unrelated donors. Their leadership of international workshops on human histocompatibility helped establish molecular typing of HLA alleles as a standard for histocompatibility testing, an approach that has been rapidly disseminated throughout the world. Subsequent studies, including by Dr. Hansen's laboratory, have demonstrated the importance of molecular matching to transplant outcomes.

The awardees were honored at ASBMT's February 2002 annual meeting in Orlando. The award is co-sponsored by an unrestricted educational grant from Pharmacia Corporation.



**John Hansen, M.D.**

## Lloyd Old Honored with Inaugural Coley Lifetime Achievement Award

Dr. Lloyd J. Old (AAI '71), director of the Ludwig Institute for Cancer Research in New York, recently received the first ever Coley Lifetime Achievement Award. The award, in recognition of Dr. Old's contributions to the field of immunotherapy, was presented by Coley Pharmaceutical Group. The company is a privately held biotechnology firm that develops immunotherapeutics for treating cancer, infectious disease, allergy, and asthma. It is named in honor of William B. Coley, M.D., considered the "father of cancer immunology".

In announcing the award, the Cancer Research Institute (CRI) cited Dr. Old's service as director of CRI's Scientific Advisory Council for three decades and as CRI trustee for two terms totaling 16 years. The award honors a distinguished career marked by passion for cancer immunology and utmost scientific integrity, first as a research fellow at Sloan-Kettering Institute for Cancer Research and continuing at the Ludwig Institute.

The Coley Lifetime Achievement Award will be awarded every two years and includes a \$10,000 honorarium; Dr. Old donated his honorarium to CRI. A member of the National Academy of Sciences, Dr. Old is also founding president of the Academy of Cancer Immunology and recipient of the prestigious Robert Koch Prize and the Robert Roesler de Villiers Award.

## Allan Goldstein Collaborating on New Tropical Disease Center

Dr. Allan Goldstein, Ph.D. (AAI '71), Chairman, Department of Biochemistry and Molecular Biology, George Washington University (GW), is helping spearhead the university's involvement in the establishment of a center for the study of tropical diseases in Panama.

Dr. Goldstein traveled to Panama late last year as part of a GW delegation collaborating with the government of Panama on a Center for the Study of Tropical Diseases and Genomic Studies in Santiago de Veraguas, Panama. In a meeting with Panama's president, Mirey Moscoso Rodriguez, the delegation signed a memorandum of understanding surrounding collaboration on the center, which will investigate the major diseases of Central America and the Caribbean. The initiative will allow GW and the Panamanian government to explore the application of new biotechnology to major diseases of the region, while providing new research opportunities both for Panamanian medical and scientific students as well as GW students, professors, and physicians involved in the work of the Center.

Dr. Goldstein served as President and Science Director at the Institute for Advanced Studies in Immunology and Aging, and as founder, chairman, and chief scientific advisor of Alpha Biomedicals, Inc., a public biotechnology company. He is the co-discoverer of thymosins, polypeptide hormones of the thymus gland, and has been issued eleven patents in that connection. He is a member of the Board of Trustees of the Sabin Vaccine Institute.

## In Memoriam

Morton Simonsen, M.D.,  
AAI Honorary Member ('97)

Professor Morten Simonsen, M.D., died in Copenhagen, Denmark, at the age of 80. He was Professor of Experimental Immunology at the University of Copenhagen from 1967 to 1991 and founding Director of the University's Institute of Experimental Immunology. Dr. Simonsen received his M.D. in 1947 and his D.Sc. dealing with renal transplant rejection in dogs in 1953, both from the University of Copenhagen.

Before he assumed his chair in Copenhagen, Dr. Simonsen was Director of the MRC Transplantation Unit at the University of Sussex (UK), a position he took at least in part as a result of the poor support of basic immunologic research in Denmark at that time. Throughout his career, Dr. Simonsen was an acknowledged member of the scientific elite, and his frequently groundbreaking work did not go unnoticed. His most important discovery was the graft-versus-host reaction, at first known as the "Simonsen phenomenon." His later elegant demonstration that as few as 50 to 100 lymphocytes sufficed to cause a graft-versus-host reaction was, for a while, a challenge to the clonal selection theories of Burnet and Jerne.



Dr. Simonsen's wisdom was freely tapped by the many Danish and international societies and councils of which he was a member. His pioneering work in transplantation immunology was recognized by his election to the Royal Danish Academy of Sciences. His many scientific honors included the Pfizer Prize, the Paul Ehrlich and Ludwig Darmstaedter Prize, the Anders Jahres Prize for Medicine, and the Novo-Nordisk Prize. He was elected to honorary membership in the American Association of Immunologists in 1997.

*Submitted by:*

*Henry P. Godfrey (AAI '97)*

*Kirsten Fischer Lindahl (AAI '88)*

*Soren Buus (AAI '89)*

*Claus Koch*

AAI extends condolences to the family, friends, and colleagues of these recently deceased members:

Boris Albini, M.D. (AAI '75)

Keith E. Jensen, Ph.D. (AAI '54)

Cesar Milstein, Ph.D. (AAI '79)

Roy Patterson, M.D. (AAI '63)

## Teachers Program Grantees Named for 2002-2003

Participants in the 2002-2003 John H. Wallace High School Teachers Program were recently announced by the program's coordinator, John R. Schreiber, M.D., M.P.H. Dr. Schreiber, a member of the AAI Education Committee, has overseen the program since the 1999-2001 year, when he succeeded the program's founding coordinator, Dr. David Scott.

The program is offered each summer by AAI and is supported through an education grant from NIAID, NIH. Aimed at promoting teaching excellence at the secondary level, the program provides support for science teachers to work for a four-week period in the laboratories of AAI members, and to complete one to two weeks of curriculum development. Participants also receive travel funds to attend the yearly John Wallace High School Teachers Workshop at the AAI annual meeting.

Science teachers selected to the program participate in a hands-on research experiment in immunology, thereby gaining insight into modern research tools and techniques. The program allows participating teachers to carry the excitement of research back to their classrooms, while establishing long-term relationships with their colleagues in the research community. It also allows AAI members who participate as mentors to have a direct impact on science education in their local school districts.

Participants and mentors for the 2002-2003 program are:

L. Dee Eller, Coupeville High School, Coupeville, WA  
Mentor: Philip Mixer, Ph.D., Assistant Professor,  
Washington State University

Thomas J. Geelan, City Honors School, Buffalo, NY  
Mentor: Elizabeth Repasky, Ph.D., Member, Roswell Park  
Cancer Institute

Dean R. Johnson, City Honors School, Buffalo, NY  
Mentor: Soldano Ferrone, M.D., Ph.D., Chairman,  
Department of Immunology, Roswell Park Cancer Institute

Mari Michele Knutson, Lynden High School, Lynden, WA  
Mentor: B. Paige Lawrence, Ph.D., Assistant Professor,  
Washington State University

Lindsay E. Porter, Pollard Middle School, Needham, MA  
Mentor: Rao H. Prabhala, Ph.D., Senior Staff Scientist, Dana  
Farber Cancer Center

Beth-Ann Shepley, Avon High School, Avon, MA  
Mentor: John G. Gribben, M.D., D.Sc., Associate Professor  
of Medicine, Dana Farber Cancer Institute

Next year's John Wallace High School Teachers Workshop will be held during Immunology 2003, AAI's 90<sup>th</sup> Year Annual Meeting, May 6-10, 2003, in Denver, CO.

# AAI Awardees Honored at Experimental Biology 2002

## Sankar Ghosh, Ph.D.

Yale University School of Medicine professor Sankar Ghosh received the **2002 AAI-PharMingen Investigator Award** and



presented the award lecture on Monday, April 22. Dr. Ghosh was nominated by Stephen Smale, Ph.D., (HHMI-UCLA) and David Baltimore, Ph.D. (Cal Tech).

Dr. Ghosh is a Yale University School of Medicine professor and Howard Hughes Medical Institute associate investigator. His

nominators described him as a world leader in studying the mechanisms through which NF- $\kappa$ B is regulated in cells of the immune system, and cited his future potential to remain an internationally recognized leader in the field. Hailed for his exceptional talents as a protein biochemist who succeeded in cloning the gene encoding NF- $\kappa$ B's p50 subunit, Dr. Ghosh was cited for compiling, in a relatively short period, a professional research and publishing record comparable to that of far more senior investigators working in his field.

Originated in 1993 as the "AAI Young Investigator Award", this award was sponsored by PharMingen in 1997 and became known as the AAI-PharMingen Investigator Award. Sponsorship has since been assumed by BD Biosciences, parent company of today's PharMingen. Past recipients of the award include Art Weiss, B. J. Fowlkes, Alessandro Sette, Pam Bjorkman, John Monaco, Chris Goodnow, Alexander Rudensky, Gary Koretzky, and Leslie Berg.

The AAI-PharMingen Award confers a commemorative plaque, travel expenses to the annual meeting, and a \$3,000 cash prize. Nominees and nominators must be AAI members; nominees must be early career scientists (i.e., having earned their doctorate 15 or fewer years prior to nomination). Candidates are ranked by the AAI Awards Committee and final selection is approved by the AAI Council.

## Mark K. Jenkins, Ph.D.

University of Minnesota professor Mark Jenkins was presented the **2002 AAI-Huang Foundation Meritorious Career Award** and delivered the award lecture on Sunday, April 21. Dr. Jenkins was nominated by Matthew F. Mescher, Ph.D. (University of Minnesota).



Dr. Jenkins, Associate Director of the University of Minnesota's Center for Immunology, was described by nominators as one of the very best scientists of his generation. He was the first to clearly demonstrate the phenomenon of anergy in T cell clones, and later demonstrated the "two-signal" requirement for T cell

activation. In part through his direct impact, 'clonal anergy' and the 'two-signal' requirement have become central concepts of T cell biology. Similarly, he is widely noted for his landmark 1994 study establishing an experimental model for studying T cell activation and tolerance *in vivo*, a model that became the standard by which countless subsequent investigators approached diverse questions impacting immunology.

This award was established in 1999 with a ten-year endowment from the Huang Foundation and its founder, Dr. Ernie Huang, Ph.D. (AAI '86). Nominees must be mid-career AAI members; they are selected by the Awards Committee and approved by Council. A \$10,000 prize, commemorative plaque, lecture, and travel expenses to the annual meeting comprise the award.

## William E. Paul, M.D.

Past AAI president William Paul was the recipient of the **2002 AAI Lifetime Achievement Award**, conferred during James Allison's Presidential Address on Saturday, April 20.



Dr. Paul has been chief of NIAID's Laboratory of Immunology since 1970, and served as director of the Office of AIDS Research (OAR) at NIH and as Associate NIH Director for AIDS Research from 1994-1997. Dr. Paul is also widely known for his discovery of, and extensive body of research on, interleukin-4 (IL-4), including work demonstrating IL-4 as the principal regulator of allergic inflammatory diseases. He has made similar, major contributions to understanding the means through which T lymphocytes recognize and respond to antigen, as well as the means through which B lymphocytes develop and how engagement of cell surface receptors control their activation. He is credited with establishing OAR as the prime mover behind national AIDS research policy and with helping spur a more than 50% increase in the number of AIDS research grants funded by NIH during his tenure as OAR Director.

Among many honors and distinctions, Dr. Paul is a member of the National Academy of Sciences, fellow of the American Academy of Arts and Sciences, past president of AAI ('85) and the American Society for Clinical Investigation, founding editor-in-chief of the *Annual Review of Immunology*, and editor of the advanced textbook *Fundamental Immunology*, now in its fourth edition.

The Lifetime Achievement Award represents AAI's highest honor, and is conferred annually at the discretion of the AAI Council. An illuminated plaque featuring hand calligraphy is presented to the awardee. The award originated in 1994; past recipients include David Talmadge, Elvin Kabat, Frank Fitch, Herman Eisen, Leonard Herzenberg, Henry Metzger, Max Cooper, and Charles Janeway.

## AAI Awardees (cont'd from p. 12)

### Ellen S. Vitetta, Ph.D.

Past AAI President Ellen Vitetta was the recipient of the **2002 AAI Excellence in Mentoring Award**, presented during the AAI Business Meeting and Awards Ceremony on Monday, April 22. Dr. Vitetta was unable to receive her award in person; Dr. Richard May, a former student and fellow in Dr. Vitetta's lab, accepted on her behalf.

Dr. Vitetta is a professor of biology and director of the Cancer Immunobiology Center at UT Southwestern. The award recognizes Dr. Vitetta's exceptional dedication and accomplishment in mentoring trainees. In her nomination materials, Dr. Vitetta was cited for the extraordinary time, effort, and care she has devoted to trainees, including her persistent challenge to "prove it" -- i.e., to go the last mile in proving the conclusions their data purports to demonstrate. This devotion has helped her trainees achieve final results consistently worthy of publication in outstanding immunology journals and to truly make contributions to the field. Her nominators and supporters further documented her status as an exemplary role model for women scientists, noting that over a third of Dr. Vitetta's 76 trainees have been women.



Dr. Vitetta was nominated by Virginia Sanders, Ph.D. (AAI '88), and Nancy E. Street, Ph.D. (AAI '91). The AAI Awards Committee reviews nominations and recommends a recipient for Council's final approval. The mentoring awardee receives a plaque featuring hand calligraphy. Since its inception in 1998, this award has been given to Matthew Scharff, Ray Owen, Mike Bevan, and Baruj Benacerraf.

### Frank W. Fitch, M.D., Ph.D.

AAI past president and current editor-in-chief, Frank Fitch, received the **2002 AAI Distinguished Service Award** during the AAI Business Meeting and Awards Ceremony on Monday, April 22. AAI President James Allison presented the award on behalf of Council, citing Dr. Fitch's very distinguished service since 1997 as *The JI*'s editor-in-chief.

Since 1996, Dr. Fitch has been Professor Emeritus, Department of Pathology and the Ben May Institute, University of Chicago. He earned his M.D. (1953) and Ph.D. (1960) from the University of Chicago, and became a full professor there in 1967. He has chaired the university's Committee on Immunology and served as director of the Ben May Institute and as Deputy Director of the university's Cancer Research Center. His more than 240 publications attest to his sustained contributions and excellence in T cell biology.



Just prior to becoming editor-in-chief of *The JI*, Dr. Fitch

received AAI's Lifetime Service Award in 1996. He served *The JI* as an associate editor (1971-77), section editor (1983-87), and deputy editor (1987-92). He chaired AAI's Publications Committee (1985-87 and 1995-96), and chaired AAI Awards Committee (1994-97). He was elected to the AAI Council in 1987 and served through 1994, including as AAI president (1992-93). As *The JI* editor in chief, he serves as an *ex officio* member of Council. Dr. Fitch also served on FASEB committees (Publication, Public Affairs, Public Affairs Executive Committee) and the FASEB Board (1991-94). He was FASEB President in 1993-94. In addition to *The JI*, his editorial activities have included *The American Journal of Pathology*; *Journal of Molecular and Cellular Immunology*; *Experimental Pathology*; *Hybridoma*; and *Chemical Immunology*.

Recent past Distinguished Service Awardees include Lewis Lanier (2001); Robert Rich (1999); Peter Lipsky, Harvey Colten, and Paul Kincade (1998); and Stephen Hedrick (1997).

## Fulbright Awards Deadline Is August 1

Fulbright Scholar awards in public health are available in a variety of specializations and countries in 2003-04, including in the Middle East and Asia.

Applications are now being accepted for post-doctoral research and/or university lecturing in public health, nursing, health education and other specializations in India, Lebanon, Indonesia, and Vietnam. Applicants must be U.S. citizens, have the terminal degree in their field, a record of publication, and university teaching experience. Awards are for three to ten months and include travel and living expenses for a grant holder and family. Visit [www.cies.org](http://www.cies.org) for additional information and application materials.

For information on the Middle East and South Asia, contact Gary Garrison at 202-686-4019 or [ggarrison@iie.org](mailto:ggarrison@iie.org). For Vietnam and Indonesia, contact David Adams, 202-686-4021, [dadams@cies.iie.org](mailto:dadams@cies.iie.org). Application deadline is August 1, 2002.

## National Academy (cont'd from p. 9)

**Lawrence**, H. Sherwood; **Marrack**, Philippa; **McDevitt**, Hugh O.; **Metzger**, Henry; **Miller**, Jacques F. A. P.; **Mitchison**, N. Avrion; **Nathanson**, Stanley G.; **Nossal**, Gustav J.; **Old**, Lloyd J.; **Paul**, William E.; **Potter\***, Michael; **Rajewsky**, Klaus; **Robbins\***, Frederick C.; **Scharff**, Matthew D.; **Schlossman**, Stuart F.; **Sela**, Michael; **Steinman**, Ralph M.; **Talmage**, David W.; **Uhr**, Jonathan W.; **Unanue**, Emil R.; **van Rood**, Johannes; **Vitetta**, Ellen S.; **Waldmann**, Thomas A.; **Weigert**, Martin G.; **Weissman**, Irving L.; **Zinkernagel**, Rolf M.

(\* = not an AAI member)

Additional information about the NAS is available at <http://national-academies.org>. A full directory of NAS members may be viewed at <http://national-academies.org/nas>.

## AAI Welcomes New Members

AAI welcomes the following new members, approved on April 1, 2002:

Arlaud, Gerard Ph.D.  
Arulanadam, Bernard M.A., Ph.D.  
Bangia, Naveen Ph.D.  
Bar-Or, Amita MDCM, M.Sc., FRCPC  
Barry, Michael B.S., Ph.D.  
Belyakov, Igor M.D., Ph.D.  
Bhardwaj, Nina M.D., Ph.D.  
Binder, Robert Ph.D.  
Colamonici, Oscar M.D.  
Dabbagh, Karim Ph.D.  
Dao, Tao Ph.D.  
DeKrey, Gregory Ph.D., B.A.  
Doherty, Derek B.A., M.Sc., Ph.D.  
Elkins, Karen B.A., Ph.D.  
Fan, Zusen M.D., Ph.D.  
Frazer, Ian M.D.  
Fry, Terry M.D.  
Gabay, Cem M.D.  
Gangur, Venugopal, Ph.D.  
Garrett-Sinha, Lee Ann B.A., Ph.D.  
Geng, Jian-Guo M.D., Ph.D.  
Gorelik, Leonid Ph.D., M.S., B.S.  
Grande, Andres B.S., Ph.D.  
Guevara Patino, Jose Ph.D.  
Guyre, Cheryl Ph.D., B.S.  
Hope, Michael B.Sc., Ph.D.  
Horuzsko, Anatolij M.D., Ph.D.  
Jabri, Bana M.D., Ph.D.  
Jen, Chausing Ph.D.  
Jung, Jaeho Ph.D.  
Kaliyaperumal, Arunan Ph.D., M.S., B.S.  
Karandikar, Nitin Ph.D., M.D.  
Karlsson, Lars M.D., Ph.D.  
Kellems, Rodney Ph.D.  
Kitagawa, Seiichi M.D.  
Kiu, Ying M.D., Ph.D.  
Klimuk, Sandra Ph.D., B.Sc.  
Kuwana, Masataka M.D., Ph.D.  
Leid, Jeff Ph.D.  
Lerner, Adam M.D.  
Levy, Frederic Ph.D.  
Liang, Bailin Ph.D.  
Livingstone, Alexandra B.Sc., Ph.D.  
MacDonald, Glen Ph.D.  
Marchese, Rocio Ph.D., B.S.  
McCune, Joseph A.B., M.D., Ph.D.  
Mehrad, Borna M.D.  
Min, Wei-Ping Ph.D., M.Sc., M.D.  
Montor, Jorge BS, MSc, Ph.D.  
Morse, Mohamad D.V.M., M.Sc., Ph.D.  
Mui, Barbara B.Sc., Ph.D.  
Mummert, Mark Ph.D.  
Nadel, Jay M.D.  
Nakajima, Atsushi M.D., Ph.D.  
Newberry, Rodney B.A., M.D.  
O'Barr, Stephen Ph.D.  
Oravecs, Tamas Ph.D.  
Pan, Qilin Ph.D.  
Parajuli, Prahlad Ph.D., M.Phil, M.Sc.  
Perlman, Stanley M.D., Ph.D.  
Petersen, Jacob  
Pippig, Susanne Ph.D.  
Plaksin, Daniel Ph.D.  
Prell, Rodney Ph.D.  
Ransohoff, Richard M.D.  
Richalet-Secordel, Pascale Ph.D., M.S., B.S.  
Santori, Fabio Ph.D.  
Sohn, Jeong-Hyeon M.D.  
Souto-Carneiro, Maria Ph.D.  
Striebich, Christopher M.D.  
Sur, Sanjiv M.D.  
Tamura, Shin-ichi Ph.D.  
Tamura, Tomohiko Ph.D., M.D.  
Tanaka, Yoshiyuki Ph.D., M.D.  
Taylor, Naomi Ph.D., M.D., M.Sc., B.A.  
Terrazas, Luis Ph.D.  
Varma, Tushar Ph.D.  
Wang, Zhuozhi Ph.D., M.D.  
Wooten, Ronald M.D., Ph.D.  
Xie, Shangkuai M.D., Ph.D.  
Xu, Biying, M.D., Ph.D.  
Xu, John B.S., Ph.D.  
Yang, Gaoyun Ph.D., M.D.  
Yang, Jinghua Ph.D.  
Yang, Yongguang M.D., Ph.D.  
Yoder, Jeffrey Ph.D.  
Yonemitsu, Yoshikaz Ph.D., M.D.  
Yu, Shiguang Ph.D.  
Zavazava, Nicholas M.D., Ph.D.  
Zhang, Pingxia Ph.D.  
Zhu, Kui Ph.D., M.S., B.Sc.  
Zoetewij, Paul Ph.D.

***Regular and Trainee Membership applications are available at pages 22-23. For complete details on becoming, or sponsoring, an AAI member, visit <http://www.aai.org/Membership>.***

# A great annual meeting doesn't grow on trees!

## THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

gratefully acknowledges its annual meeting sponsors for their generous provision of unrestricted educational grants in support of Experimental Biology 2002

### **Amgen Inc, Thousand Oaks, CA**

*General Meeting Support*

### **Aventis Behring - North America, King of Prussia, PA**

*AAI Distinguished Lecture: Genetic Manipulation of the Immune Response*

### **BD Biosciences, La Jolla, CA**

*EB 2002 Meeting Bags*

*AAI Annual Gala*

*AAI President's Reception*

*AAI-Pharmingen Investigator Award and Lecture*

### **Burroughs Wellcome Fund, Research Triangle Park, NC**

*AAI Major Symposium: Immunologic Memory*

### **Cadmus Professional Communications, Richmond, VA**

*The Journal of Immunology Editorial Board Dinner and Meeting*

### **Henry J. Showell, Ph.D., Groton, CT**

*Pfizer-Showell Travel Award*

### **Huang Foundation, Rancho Santa Fe, CA**

*AAI-Huang Foundation Meritorious Career Award*

*AAI-Huang Foundation Trainee Achievement Awards*

*UT Southwestern Texas Party*

### **Juvenile Diabetes Research Foundation International, New York, NY**

*Major Symposium H: Genetics & Genomics of Autoimmune Disease*

### **Medarex, Inc., Princeton, NJ**

*Presidential Address: Tumors to T Cell and Back Again*

### **Merck Research Laboratories, Rahway, NJ**

*General Meeting Support*

## Testimony (cont'd from p. 4)

With all of this research ongoing, immunologists are poised to embrace a new and unexpected research challenge posed by the FY 2003 budget: bioterrorism research. AAI members include the nation's preeminent immunologists, many of whom will conduct the research that will be at the forefront of the nation's urgently needed vaccine development and related bioterrorism research efforts. The efforts of immunologists will be critical in understanding both the mechanism of infectious diseases and recovery from them. As we discuss this year's budget, we would also like to discuss the unique role that we believe immunologists can play in the national effort to combat bioterrorism.

### **Doubling the budget of the National Institutes of Health (NIH)**

AAI strongly supports the President's budget request for \$27.3 billion for FY 2003 for the NIH – an increase of 15.7% (\$3.99 billion) over FY 2002. This request, if funded, would complete the doubling of the NIH budget over five years - a bipartisan effort made by Congress under the leadership of the then-Chairman and ranking member of this subcommittee, Rep. John Porter (R-10th, IL, ret.) and Rep. David Obey (D-7<sup>th</sup>, WI), and the then-Chairman and ranking member of the Senate Appropriations Subcommittee on Labor, Health and Human Services, and Education, Senators Arlen Specter (R-PA) and Tom Harkin (D-IA). This doubling effort has been endorsed and fulfilled by President Bush in his FY 2002 and FY 2003 budget requests.

Prior years' funds have already increased the funding of grants to about 30% of all submitted applications, allowing for more quality research and for a greater likelihood of successful grant applications. The FY 2003 budget would build on this foundation. Most Institutes and Centers would receive an average increase of 9%, with the NIAID increasing by 52% and the NCI increasing by 11%. NIH expects that the FY 2003 budget would fund a total of 9,854 new, competing research grants, resulting in the highest annual total ever (38,038 awards). In addition, intramural research would increase by about 15% over FY 2002.

AAI believes that this increase in funding will allow more quality research to be funded, leading to more translational opportunities and swifter clinical application. It will also help attract young students to research careers and help retain young scientists who might otherwise leave academia or government for better funding opportunities with pharmaceutical or biotech companies.

### **Bioterrorism funding**

As the members of this subcommittee know, a significant portion of this year's budget increase - \$1.75 billion - is devoted to bioterrorism research, with \$1.5 billion of that total directed to the National Institute of Allergy and Infectious Diseases (NIAID). AAI strongly supports the President's extraordinary commitment to research evidenced by this funding request. And while we as scientists generally oppose specific funding earmarks - preferring instead to allow investigator initiated research to lead us to the next scientific discoveries - we recognize the responsibility of the President and the Congress to address urgent national needs and to direct funding to areas where scientists may not currently be focusing their attention or

efforts. A previous example was the advent of AIDS in the 1980s, when little or nothing was known of the disease. During a tumultuous period lasting through much of that decade, the scientific community was asked to focus on this emerging pandemic. And while we are still a long way from curing AIDS, the research that has been done on the cause, epidemiology, and prophylaxis has prevented untold numbers of new cases of AIDS; and advanced treatments have enabled millions of people with AIDS or HIV to live longer, healthier lives. It was the NIAID, under the exceptional leadership of Dr. Anthony Fauci, together with thousands of scientists who are funded by the NIAID, that changed the course of the fight against AIDS/HIV. AAI members firmly believe that Dr. Fauci and the NIAID will be able to lead the national research effort against bioterrorism as successfully as they did the fight against AIDS, and we feel confident – as a significant portion of the NIAID's grantees - that we can undertake with purpose and commitment the research challenges that Dr. Fauci and the NIAID have laid out for us.

### **The roles for immunologists in the national response to bioterrorism.**

Because immunologists study the immune system in health and disease, we have both a special interest and expertise in the nature of infections. We have a unique ability to study the normal immune response to the bacteria and viruses which could be used as weapons of bioterrorism. An important aspect of the normal immune response is defining the "targets" (i.e., antigens or epitopes) the immune system uses to recognize and destroy invading pathogens. In immunologic terms, this means defining the chemical nature of the epitopes recognized by the major defenders of the immune system - T and B lymphocytes. The mechanisms of defining epitopes are well known, but have not been applied to some pathogens which could be used as weapons of bioterrorism; these will need to be defined in the test tube, in animal models,<sup>2</sup> and finally, in humans. Once we understand the human immune response, we will be prepared to develop life-saving therapies and preventive vaccines. Collaboration between microbiologists, who understand the biology of infectious agents, and immunologists, who understand how the immune system recognizes and fights infectious agents, is critical.

Many diseases have serious health consequences that can reappear years after the primary infection (e.g., some autoimmune syndromes). Many of these disorders are related to immune responses to persistent infection. It is important to understand these possible negative effects of immune system protection. An understanding of the biology of these negative effects will allow physicians to predict the likely side effects and/or long-term consequences of both vaccination and contracting the disease itself. The benefit of these studies includes the following:

1. These studies will lead to the production of safe and effective vaccines. This information will allow vaccines to target the correct parts of the pathogens and make the vaccine more effective, while at the same time less likely to induce side effects.
2. Immunologists will provide tools for clinicians to aid in the rapid diagnosis and prognosis of infected individuals. This could include both monoclonal antibody-based tests to detect the

*see iTestimonyi, p. 17*

## Testimony (cont'd from p. 16)

presence of an infectious agent as well as assessments of immune status to aid in the determination of the course of infection.

3. The course of the disease will itself suggest effective treatments. Understanding the disease process will define targets for drug therapy that are specific, e.g., antitoxin treatment used for tetanus. Once these targets are identified, the real strengths of the American pharmaceutical industry (rapid drug screening and development) can be utilized.

### **Research, Management and Services (RM&S) budget**

AAI applauds the President and the leadership at NIH for recommending a budget which recognizes that significant new funding requires additional administrative staff to ensure that the money is well and properly spent. While the Research, Management and Services (RM&S) budget supports the management, monitoring, and oversight of intramural and extramural research activities (including ensuring the continuation of NIH's excellent and highly regarded peer review process), it has not been able to keep pace with the increasing size and complexity of the NIH budget. We are particularly pleased, therefore, that the RM&S budget receives an overall increase of 17% in FY 2003, with an average 9% increase for most Institutes and Centers and a larger increase for the NIAID and NCI to support their significant funding increases. AAI believes that proper stewardship will be the best guarantee the taxpayer and the Congress have that the appropriated funds will support the best research and lead to the most promising results. We strongly support this increase in the RMS budget and hope that hiring procedures can be streamlined and, if necessary, amended, so that hiring can be accomplished in time for the upcoming grant cycles and new funds can be awarded expeditiously.

### **Attracting bright students to biomedical research and retaining young researchers**

AAI has long been concerned about science's ability to attract bright young students to careers in biomedical research to ensure the future supply of biomedical researchers. In particular, we have worked to advance the plight of post-doctoral fellows who are significantly underpaid and under-compensated for their critical work. We were pleased, therefore, when the NIH announced in March of 2001 that it intended to implement recommendations of the National Academy of Sciences' Committee on Science, Engineering, and Public Policy (COSEPUP) regarding the need for better compensation and employment benefits for post-doctoral fellows. (See NIH NOT-OD-01-027). The final NIH plan included increasing the stipends for National Research Service Award (NRSA) recipients over a five year period by 10% per year or until entry level post-doctoral fellows reach \$45,000 per year (from its FY 2002 level of \$31,092). During FY2002, NIH did raise stipends by 10% and intended to raise them again during FY 2003 by 10%. The President's budget, however, permits only a 4% increase for FY 2003.

We strongly urge this subcommittee to allow NIH to proceed with its plan to increase NRSA post-doctoral stipends and to further explore ways to provide important employment benefits -

including health insurance, pensions and Social Security, and vacation/leave time - to both NRSA's and the post-doctoral fellows supported by NIH extramural grants. While we understand that this may result in the hiring of fewer post-doctoral fellows, we believe that it is essential to provide a living wage and basic employment benefits if we are to attract and retain the best and brightest students who often encounter multiple job opportunities with significantly more attractive compensation packages. NIH and the National Science Foundation have both recognized this reality facing the nation's scientific community and have attempted to address this problem directly - we urge the Congress to enable NIH to move forward with its post-doctoral stipend plan.

### **Salary Cap**

The President's FY 2003 budget request includes a provision which was rejected by the Congress last year to lower the existing salary cap for extramural researchers. This proposal to "roll back" current law would result in a 10% reduction in salary support for some extramural researchers and cause serious administrative and budgetary problems within research institutions, medical schools, and universities that are preparing or have already prepared budgets based on the higher salary cap previously permitted by the Congress. We urge this subcommittee and the Congress to remove this provision and to retain current law.

### **Post-doubling budgets**

AAI members are grateful for the extraordinary support for biomedical research that the Congress has shown through the successful and nearly completed effort to double the NIH budget. While we recognize that such generous funding increases are unlikely to continue in future years given the many important competing programs and needs, we strongly urge the Congress to preserve and build upon the many scientific advances that have been - and will continue to be - made during the doubling period by ensuring adequate funding increases in the post-doubling era. While AAI has not yet formulated a recommendation regarding reasonable funding increases for future years, we note that NIH Acting Director Ruth Kirschstein, M.D., in testimony to the Senate Appropriations Subcommittee on Labor, Health and Human Services, and Education on March 21, 2002, indicated that current scientific opportunities "lend themselves to an 8-10% [annual] increase" in funding in the post-doubling years. We urge the Congress to continue to nurture and support the nation's scientific and biomedical research enterprise as a prudent investment in providing healthier, better, and safer lives for all Americans.

### **Conclusion**

While ongoing hearings in Congress continue to explore details of the President's FY 2003 biomedical research budget that AAI has not yet completed studying, we regard the President's FY 2003 budget for NIH as evidencing an extraordinary commitment to advancing not only our nation's defenses against bioterrorism, but also the fight against the more common diseases which afflict every family in America and around the world, and wreak havoc - one person - and one family - at a time. We look forward to

*see iTestimonyi, p. 18*

## Testimony (cont'd from p. 17)

embracing the many research areas that will open to our scientists and plan to work with the NIAID to help educate bench scientists about the scientific needs and opportunities that lie before us. We hope that the members and staff of this subcommittee will look to us as a resource on any matters involving the immune system, vaccine development, or biomedical research in general. We appreciate having this opportunity to express our views.

Footnotes:

<sup>1</sup> Many AAI members also receive grants from the National Cancer Institute (NCI), the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin

Diseases (NIAMS), the National Heart, Lung, and Blood Institute (NHLBI), and other NIH Institutes and Centers.

<sup>2</sup> Immunologists depend heavily on the use of animal models in their research. Without the use of animals, theories about immune system function and treatments that might cure or prevent disease would have to be tested first on human subjects, something our society - and our scientists - would never countenance. Despite the clear necessity for animal research, people and organizations that oppose such research are threatening scientists who use animal models. The legal and illegal methods used by these groups to further an animal-rights/anti-medical research agenda are diverting precious resources from our work, threatening the personal safety and security of scientists, and delaying the progress of important research that is already underway.

**Thanks...**

...to AAI's 2002 Block Co-Chairs for providing their time and expertise in reviewing and assigning abstracts submitted for AAI Block and Poster sessions at EB 2002.

Michael Carroll, Ph.D.  
David D. Chaplin, M.D., Ph.D.  
Harold Chapman, M.D.  
Matthew J. Fenton, Ph.D.  
JoAnne Flynn, Ph.D.  
Stephen Galli, M.D.  
Michael J. Grusby, Ph.D.

Frederick P. Heinzel, M.D.  
Gary A. Koretzky, M.D., Ph.D.  
Vijay Kuchroo, D.V.M., Ph.D.  
Leo Lefrancois, Ph.D.  
Richard M. Locksley, M.D.  
Clifford Lowell, M.D., Ph.D.  
Olivia Martinez, Ph.D.

Elizabeth Mellins, M.D.  
James Mule, Ph.D.  
Kenneth M. Murphy, M.D., Ph.D.  
Michel Nussenzweig, M.D., Ph.D.  
Pamela S. Ohashi, Ph.D.  
Shiv Pillai, Ph.D.  
Mark Schlissel, M.D., Ph.D.

Robert A. Seder, M.D.  
Walter J. Storkus, Ph.D.  
Thomas F. Tedder, Ph.D.  
Laurence Turka, M.D.  
Dale Umetsu, M.D., Ph.D.  
Matthias G. Von Herrath, M.D.  
Caroline C. Whitacre, Ph.D.

 <h3 style="text-align: center;">42nd Annual Meeting</h3> <p style="text-align: center;"><b>December 14–18, 2002 • Moscone Convention Center • San Francisco</b>  <small>Gary Borisy, President; John Cooper, Program Chair; Patricia Calarco, Local Arrangements Chair</small></p> <p style="text-align: center;"><b>Keynote Symposium: Opportunities &amp; Challenges in Cell Biology</b>  <small>Saturday, December 14 - 6:00 pm</small>  <small>Steven M. Block, R. Alta Charo, Ron McKay, Andrew W. Murray</small></p>			
<b>Symposia</b>		<b>Minisymposia</b>	
<p><b>Nuclear Trafficking and Dynamics</b> Ian G. Moore David Spector Joan A. Stett</p> <p><b>How Cells Interact with Each Other</b> Bonnie Bassler David A. Cheshoff Peter Devreotes</p> <p><b>Cell Biology of Cancer</b> Doergin Henschler Jeffrey Trest Terry A. Van Dyke</p> <p><b>Inheritance of Organelles</b> Susan Dutcher N. Rowald Morris Lois S. Weisman</p>	<p><b>Chromatin and Chromosomes</b> C. David Allis Kerry S. Noon Marjori Matzke</p> <p><b>Cell Division: New Paradigms for Regulation of Timing and Size</b> Greenfield Sluder Michael Tyers Mitsuhiko Yanagida</p> <p><b>Cell Polarization and Directional Motility</b> Anthony Bretscher Ruth Lehmann Frederick Maxfield</p> <p><b>Signal Transduction Pathways in Development</b> Guil R. Martin Randall T. Moon Alex Schier</p>	<p><b>Apoptosis and Cellular Senescence</b> Cell Biology of Angiogenesis Cell-Cell Junctions Cell Cycle Regulation Cell Junctions and Signal Transduction Cell Migration Cell Polarity: Establishment &amp; Maintenance Computational Approaches to Cell Biology Control of Growth, Size and Shape Cytokinesis Cytoskeletal Dynamics in Living Cells Cytoskeletal Motors Cytoskeletal Processes During Development Endocytosis ECM Molecules and their Receptors</p>	<p><b>Extracellular Matrix and Cancer</b> Integrin Signaling Mechanisms of Cell Signaling Meiosis and Germ Cells Microbial Pathogenesis Mitotic Spindle Assembly and Function Nuclear Structure and Function Nucleocytoplasmic Trafficking Organelle Biogenesis and Inheritance Protein Folding and Quality Control in the ER Rafts and Other Membranes Microdomains Regulation of Cytoskeleton Assembly RNA Localization and Dynamics Signaling and Cell Proliferation Signaling and Development Stem Cells Vesicle Trafficking</p>
<p>For more information, contact the ASCB at 301-347-9300; <a href="mailto:ascbinfo@ascb.org">ascbinfo@ascb.org</a>; <a href="http://www.ascb.org">www.ascb.org</a>. Abstract Submission Deadline: August 1</p>			

# MEETING ANNOUNCEMENTS

## 2002

**Jun. 23-26** *12th International Symposium on Infections in the Immunocompromised Host*, Bergen, Norway

Sponsored by International Immunocompromised Host Society

Abstract deadline: March 31, 2002

Advance registration deadline: June 15, 2002

Contact: Meeting Secretariat: 12th International Symposium, 3224

Brooksong Way, Dacula, GA 30019,

Phone: (770) 271-8817 \* Fax: (770) 271-3317

E-mail: [wsnow@bellsouth.net](mailto:wsnow@bellsouth.net)

**Jun. 23-27** *14th Germinal Centre Conference*, Groningen, the Netherlands -- Held under the auspices of the Dutch Society for Immunology (Nvvi) and the European Federation of Immunological Societies (EFIS)

Contact: K.F. Wenckebach Instituut Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands

Phone: 31 050 361 2745 \* Fax: 31 050 361 1819

Email: [info@wenckebachinstituut.nl](mailto:info@wenckebachinstituut.nl)

Web: [www.wenckebachinstituut.nl](http://www.wenckebachinstituut.nl)

**Jun. 24-25** *Inflammation in Drug Discovery and Development*, Princeton Marriott, Princeton, N.J.

Contact: Strategic Research Institute, Cheryl Kahan-Radhuber, 333 Seventh Ave., 9th Floor, New York, NY 10001

Phone: (212) 967-0095

**Jun. 25-29** *Fifth International Weber Symposium on Innovative Fluorescence Methodologies in Biochemistry and Medicine*, Kalapaki Beach, Lihue, Hawaii (island of Kaua'i)

Information: <http://lfd.uiuc.edu/Weber/>

**Jun. 29-Jul. 1** *FOCIS: Federation of Clinical Immunology Societies -- 2nd Annual Meeting*, Hilton San Francisco & Towers

Contact: FOCIS Meeting Mgr., 611 East Wells St., Milwaukee, WI 53202 \* Email: [focis@execinc.com](mailto:focis@execinc.com); Web: [www.focisnet.org](http://www.focisnet.org)

**Jul. 7-12** *XIVth World Congress of Pharmacology*, Sponsored by the International Union of Pharmacology, the National Academy of Sciences, U.S.A., and the American Society for Pharmacology and Experimental Therapeutics, Moscone Convention Center, San Francisco, CA.

Contact: Congress Secretariat, XIVth World Congress of Pharmacology, 9650 Rockville Pike, Bethesda, MD 20814-3995

Phone: (301) 530-7061 \* Email: [juphar@aspet.faseb.org](mailto:juphar@aspet.faseb.org)

Web: [www.iuphar.org](http://www.iuphar.org)

**Jul. 18-21** *7th Biennial Conference of the International Endotoxin Society*, The Natcher Conference Center, NIH, Bethesda, MD

Contact: Email: [rsilvers@kumc.edu/IES](mailto:rsilvers@kumc.edu/IES)

**Jul. 20-24** *The American Society for Virology 21st Annual Scientific Meeting*, Lexington, KY -- Sponsored by University of Kentucky, Lexington.

**Contact:** Sidney E. Grossberg, Secretary-Treasurer, American Society for Virology, Dept. of Microbiology and Molecular Genetics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226-0509

Phone: (414) 456-8104 \* Fax: (414) 456-6566

Email: [segrossb@mcw.edu](mailto:segrossb@mcw.edu) \* Web: [www.mcw.edu/asv](http://www.mcw.edu/asv)

**Aug. 15-18** *Third International Congress of Oncology and Immune-Biomodulation (III ICOI)*, Sao Paulo, Brazil

Organized by Sociedade Brasileira de Cancerologia/Scientific Department of the Brazilian Medical Association

Contact the Executive Secretariat: c/o Ms. Sandra Galeotti, Rua Republica do Togo, 360, 05537-110, S. Paulo, SP, Brazil

E-mail: [sbc.icoi@uol.com.br](mailto:sbc.icoi@uol.com.br) \* Tel: 55 11 3744-0710

III ICOI Program online: [www.rsbc.com.br/icoi](http://www.rsbc.com.br/icoi)

**Aug. 17-21** *16th Symposium of the Protein Society*, San Diego Marriott, San Diego, CA.

Contact: ABRF Meeting Management Office, 9650 Rockville Pike, Bethesda, MD 20814

Phone: (301) 530-7010 \* Fax: (301) 530-7014

Web: [www.faseb.org/meetings](http://www.faseb.org/meetings)

**Aug. 21-25** *2002 Congress of the Asian Forum of Immunology and Oncology*, Beirut, Lebanon

All sessions in English.

Contact: Dr. Marwan Masri, President: [info@congressorg.org](mailto:info@congressorg.org)

**Sep. 7-12** *5th EFIS Tatra Immunology Conference*, organized by the Czech, Slovak, Austrian, and British Societies of Immunology under auspices of EFIS

Contact: Dr. Vaclav Horejsi, Institute of Molecular Genetics AS CR, Videnska 1083, 142 20, Prague 4, Czech Republic

Phone: 420-2-472-9908 \* Fax: 420-2-44472282

**Sep. 8-18** *NATO Advanced Study Institute -- Frontiers In Autoimmunity: Fundamental Aspects and Clinical Perspectives*,

Keszthely, Balaton Lake, Hungary

Deadline for applications: 15 June 2002

Financial support: Limited financial support will be available for participants from NATO, Partner and Mediterranean Dialogue countries who can clearly establish that they are unable to meet all of their costs from other sources. They will be awarded on a competitive basis, taking into account the justifications made in individual requests.

**Sep. 9-11** *Fifth International Congress, Intil Society for Neuroimmunomodulation*, Le Corum, Montpeillier, France

see *iMeetings*, p. 20

## Meetings (cont'd)

Contact: Craig C. Smith, M.Sc., Integrative Neural Immune Program, NIMH, 36 Convent Drive, Room 1A23, MSC 4020, Bethesda, MD 20892-4020 \* Phone: (301) 496-4561

**Sep. 9-16** *FEBS International Summer School in Immunology*, Ionian Village, Western Peloponnes, Greece -- The Immune System: Genes, Receptors and Regulation. Suitable for senior pre-doctoral and post-doctoral investigators in related fields. Travel fellowships available for participants under age 31 from countries with a FEBS Constituent Society; fellowship applicants should be a member of his/her country's FEBS Society. CV, applicant's scientific background and interests, and one letter of recommendation should be sent no later than July 10, 2002, to: Dr. M. Papamichail, Center for Immunology, St. Savas Cancer Hospital, 171, Alexandras Ave. Athens, 11522 Greece Tel. : 30-1-6430083 \* Fax : 30-1-6409516 / 6420146 E-mail : papmail@netor.gr

**Sept. 15-18** *Fifth International Conference of the Hospital Infection Society* will be held at the Edinburgh International Conference Centre, Edinburgh, Scotland. Contact: Conference Secretariat: Concorde Services, HIS2002, Unit 4b, 50 Speirs Wharf, Port Dundas, Glasgow G4 9TB, Scotland, UK. Phone: 44 141 331 0123 \* Fax: 44 141 331 0234 Email: his@concorde-uk.com \* Web: www.his2002.co.uk

**Sept. 15-22** *British Society for Immunology and the Shemyakin Institute of Bioorganic Chemistry Sixth John Humphrey Summer Programme in Immunology, iMolecular Basis of the Immune Response* -- Puschino (near Moscow) British Coordinator: Geoffrey Asherson, 8 Wigmore Place, London W1U2LR, UK \* Tel/Fax +44-(0)207-580-3197 Email: GLAsherson@cs.com Russian Organizing Secretary: Vladimir Nesmeyanov, Shemyakin Institute for Bioorganic Chemistry, Ul Miklukho-Maklaya, 16/10, 117997 GSP-7, Moscow V-437 Tel/Fax: (007095)-330-5974 \* Email: vnes@mail.ibch.ru

**Sep. 19-24** *7th International Symposium on Dendritic Cells*, Bamberg, Germany. Contact: Dr. A. Steinkasserer, Dermatologische Klinik, Universitat Erlangen, Hartmannstr. 14, D-91052 Erlangen, Germany Phone: ++49-9131-853-6725 Fax: ++49-9131-853-5799 Email: dc2002@medacad.org \* Web: www.dc2002.de or http://www2.derma.med.uni-erlangen.de/klinik/

**Sep. 23-24** *First International Symposium, Frontiers in Ocular Immunology, Inflammation & Transplantation*, London, UK Contact: Inst. of Ophthalmology (Univ. College London), 11-43 Bath Street, London EC1V 9EL Phone: 00 44 207 608 4069 \* Fax: 00 44 207 608 4044 Email: r.ajao@ucl.ac.uk

**Sep. 26-29** *International Conference on Dipeptidyl-Aminopeptidases: Basic Science and Clinical Applications*, Berlin, Germany

Contact: Martin Hildebrandt, MD, c/o Charité, Department of Medicine/Psychosomatics, Luisenstr. 13A, 10117 Berlin, Germany \* Fax: +49-30-450-553900

**Sep. 29-Oct. 3** *10th International Congress on Antiphospholipid Antibodies*, Giardini Naxos, Taormina, Sicily, Italy Deadline for Abstracts: April 1, 2002 Contact: Secretariat, 10th International Congress on Antiphospholipid Antibodies, c/o Kenes International, P.O. Box 50006, Tel Aviv 61500, ISRAEL Tel: 972 3 5140018/9 \* Fax: 972 3 5140077 or 972 3 5172484 E-Mail: aps@kenes.com \* Website: www.kenes.com/aps

**Oct. 4** *Second Annual Immunology Meeting presented by SUNY Buffalo -- Focus: Innate Immunity*, University Inn & Conference Center (<http://www.universityinn.com/>) Contact: Susan Burkard, burkard@acsu.buffalo.edu Tel: 716-829-3831

**Oct. 5-9** *Neuroendocrine-Immune Interactions: EuroConference on Molecular Mechanisms and Clinical Relevance of Brain-Immune Communication*, San Feliu de Guixols, Spain Application deadline: June 2002 \* Scientific program, on-line application: [www.esf.org/euresco/02/mc02140](http://www.esf.org/euresco/02/mc02140) Contact: Dr. J. Hendekovic, European Science Fdn., EURESCO Unit, 1 qual Lezay-Marnesia, 67080 Strasbourg Cedex, France Phone: +33 388 76 71 35 \* Fax: +33 388 36 69 87 Email: curesco@esf.org

**Oct. 6-11** *Joint Meeting of the International Society for Interferon and Cytokine Research (ISICR), the International Cytokine Society (ICS), the European Cytokine Society (ECS) and Society for Leukocyte Biology (SLB)*, Lingotto Congress Center, Torino, Italy \* E-mail: cyto2002@marionegri.it Organizing Secretariat: M.A.F. Servizi srl - Congress department, Via G.B. Vico 7 - 10128 Torino Tel. +39 011 505 900 \* Fax +39 011 505 976 [www.mafservizi.it](http://www.mafservizi.it) \* E-mail: cyto2002@mafservizi.it

**Oct. 19-23** *The American Society of Histocompatibility and Immunogenetics 28th Annual Meeting*, Opryland Hotel and Convention Center, Nashville, TN Contact ASHI executive offices -- Tel: (856) 638-0428

**Oct. 25-29** *66th Annual Scientific Meeting of the American College of Rheumatology*, New Orleans, LA. **Contact:** American College of Rheumatology, 1800 Century Place, Suite 250, Atlanta, GA 30345-4300 Phone: (404) 633-3777 \* Fax: (404) 633-1870 Email: acr@rheumatology.org \* Web: [www.rheumatology.org](http://www.rheumatology.org)

**Oct. 30-Nov. 2** *TNF Superfamily 2002: The 9th International Congress on TNF-Related Cytokines*, Hyatt Regency on San Diego Bay, San Diego, CA Contact: Carl F. Ware, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121 Phone: (858) 558-3500 \* Web: <http://meetings.liai.org/tnf> Email: [meetings@liai.org](mailto:meetings@liai.org)

see *iMeetings*, p. 12

## Meetings (cont'd)

2003

**Nov. 2-7** *Society for Neuroscience 32nd Annual Meeting*, Orange County Convention Center, Orlando, FL  
Web: <http://www.sfn.org/AM2002Splash/cfm>

**Nov. 10-14** *51st Annual Meeting, American Society of Tropical Medicine and Hygiene (ASTMH)*, Adam's Mark Hotel, Denver, CO

Deadline: June 1, 2002, for online abstract submissions  
Online submissions at <http://abstract.cornetser.com/>  
Category I CME credit available for 30 hours.  
Contact: ASTMH, American Society of Tropical Medicine and Hygiene, 60 Revere Drive, Suite 500, Northbrook, IL 60062 USA \* Telephone 847) 480-9592  
E-mail: [astmh@astmh.org](mailto:astmh@astmh.org) \* Web: <http://www.astmh.org>.

**Nov. 10-14** *American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition*, Toronto, Ontario, CAN  
Contact AAPS Meetings, Tel: (703) 243-2800  
Fax: (703) 243-953 \* E-mail: [meetings@aaps.org](mailto:meetings@aaps.org)

**Nov. 27-29** *Annual Meeting of the French Society of Immunology; Europe-Japan Symposia in Immunology*, Palais de la Musique et des Congres in Strasbourg, France  
Contact: Prof. G. Hauptmann, Meeting Coordinator  
Phone: +33 3 90 24 39 75 \* Fax: +33 3 90 24 40 16  
Email: [Georges.Hauptmann@hemato-ulp.u-strasbg.fr](mailto:Georges.Hauptmann@hemato-ulp.u-strasbg.fr)  
Web: [www.inserm.fr/sfi](http://www.inserm.fr/sfi)

**Dec. 4-8** *2nd European Medical and Biological Engineering Conference EMBEC '02*, Vienna, Austria.  
Abstract deadline: March 15, 2002. Information (program, abstract submission, registration): <http://www.embec.org>

**Jan. 28** *Methods in Cytokine Biology IV*, National Institutes of Health, Natcher Conference Center, Bethesda, MD (Sponsored by the NIH Cytokine Interest Group)

This one-day symposium will review state of the art techniques used in the investigation of cytokine biology with an emphasis on their practical application. Registration is free and the meeting is open to all investigators. No advance registration.  
Contact: Calman Prussin (301) 496-1306 \* [calman@nih.gov](mailto:calman@nih.gov)  
Website: <http://www.nih.gov/sigs/> and scroll to "Cytokine Interest Group."

**Mar. 2-5** *Cell Transplant Society - 6th International Meeting*, Atlanta, GA. Contact: Collin J. Weber, MD, DMSci, President, Cell Transplant Society \* Website: <http://www.celltx.org/>

**Apr. 11-15** *Experimental Biology 2003 Annual Meeting*, San Diego, CA (Exhibit Show Dates: April 12-14)  
Call for Abstracts/General Info available early September 2002  
Sponsoring Societies: American Association of Anatomists; The American Physiological Society; American Society for Biochemistry and Molecular Biology; American Society for Investigative Pathology; American Society for Nutritional Sciences; and American Society for Pharmacology and Experimental Therapeutics  
Contact: [eb@faseb.org](mailto:eb@faseb.org) \* Website: <http://www.faseb.org/meetings/eb2003/>

**May 6-10** *Immunology 2003: AAI's 90th Year Annual Meeting, Denver CO*  
Contact: AAI, 9650 Rockville Pike, Bethesda, MD 20814 Phone: (301) 530-7178 \* Fax: (301) 571-1816  
Email: [infoaai@aai.faseb.org](mailto:infoaai@aai.faseb.org) \* Web: [www.aai.org](http://www.aai.org)



*Is your Directory listing correct?*

Update your online record anytime during the year.

To update your online listing in the *FASEB Directory of Members*, visit [www.faseb.org](http://www.faseb.org) and click on "Member Directory" at the left or go directly to <http://12.17.12.70/fasebdir>

Click "Update Member Info" at the top of your screen to make changes.

Please note: There is a time delay between submitting revisions and their actual appearance online.

# THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE ♦ BETHESDA, MD 20814-3994

TEL: (301) 530-7195 ♦ FAX: (301) 214-8833

FEDERAL TAX ID NO: 52-2317193

Email Address: members@aai.faseb.org ♦ Website Address: http://www.aai.org

## 2002 TRAINEE MEMBERSHIP APPLICATION FORM

Name: \_\_\_\_\_ Email Address: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_ Country \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

Students and Post-Doctoral Trainees may become Trainee members of the AAI. Trainee members will receive a subscription to *The Journal of Immunology* and the *AAI Newsletter*. **Subscriptions will start upon receipt of your application and end on December 31 of the current year.** Trainee members will also have the privilege of attending and participating (without vote) in the AAI Annual Business Meeting. In addition, they will receive all AAI announcements and correspondence.

Qualified applicants must complete the information below and return this form with the required payment. Checks are to be made payable to *The American Association of Immunologists*. All checks must be drawn on a U.S. bank and International money orders are accepted.

Individuals may remain Trainee members for a maximum of eight (8) years. Certification **must** be renewed annually.

### PRE-DOCTORAL TRAINEE

I hereby certify that \_\_\_\_\_  
(Please print clearly)

is a regularly matriculated *student* in the Department of \_\_\_\_\_

at \_\_\_\_\_  
(University or Institution)

and as such is eligible to become a Pre-Doctoral Trainee member of the AAI.

\_\_\_\_\_  
(Signature- must be an AAI member)

Name \_\_\_\_\_  
(Please print clearly)

Title \_\_\_\_\_  
(Dean, Department Chair or Professor in Charge)

Date \_\_\_\_\_

### POST-DOCTORAL TRAINEE

I hereby certify that \_\_\_\_\_  
(Please print clearly)

is a post-Doctoral Trainee in the Department of \_\_\_\_\_

at \_\_\_\_\_  
(University or Institution)

and as such is eligible to become a Post-Doctoral Trainee member of the AAI.

\_\_\_\_\_  
(Signature- must be an AAI member)

Name \_\_\_\_\_  
(Please print clearly)

Title \_\_\_\_\_  
(Dean, Department Chair or Professor in Charge)

Date \_\_\_\_\_

### PLEDGE

I \_\_\_\_\_, pledge that the copies of *THE JOURNAL OF IMMUNOLOGY* received by me as an AAI Trainee member are for my personal use. They will not be placed in a library for general use, sold, or replace a subscription currently purchased by an institution.

### 1 JANUARY - 31 DECEMBER 2002

U.S. Member

\$64.00

CHECK ENCLOSED

Canadian Member

\$158.00 (7% GST Incl.)

VISA

International Member

\$154.00

MASTERCARD

CARD NUMBER: \_\_\_\_\_ EXPIRATION DATE: \_\_\_\_\_

SIGNATURE: \_\_\_\_\_

**TO HELP REDUCE OUR CREDIT CARD PROCESSING FEES, WE WOULD APPRECIATE YOUR PAYMENT BY CHECK.**

**THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS**

9650 ROCKVILLE PIKE ♦ BETHESDA, MD 20814-3994

TEL: (301) 530-7195 ♦ FAX: (301) 214-8833

FEDERAL TAX ID NO: 52-2317193

Email Address: members@aai.faseb.org ♦ Website Address: http://www.aai.org

**QUALIFICATIONS AND APPLICATION FOR REGULAR MEMBERSHIP  
2002 MEMBERSHIP YEAR**

The American Association of Immunologists (AAI) is a professional organization whose members have a strong interest in, and have made substantial contributions to, the science of immunology. AAI is a member of the Federation of American Societies for Experimental Biology (FASEB) and is responsible for the publication of *The Journal of Immunology*. To be eligible for election to membership in the AAI, a candidate must meet **one** of the following criteria:

1. Possess a Ph.D. (or equivalent graduate degree, *e.g.*, D.Sc.) in immunology or related disciplines, or an M.D. (or equivalent medical degree, *e.g.*, D.D.S.) and be the **first** author of **one** significant original publication on an immunological topic in a reputable, **English language**, refereed journal. Manuscripts "in press" are acceptable when accompanied by a letter from the publisher or Editor-In-Chief of the journal affirming its acceptance and imminent publication. Abstracts and unpublished papers **will not** be considered in evaluating whether a candidate meets the publications requirement for membership. The requirement for an advanced degree can be waived in certain circumstances if the candidate shows evidence of other appropriate training and research experience.\*
2. Be an established scientist with substantial achievement in a related discipline and have at least one collaborative paper on an immunological topic in a reputable, **English language**, refereed journal.

*\*These requirements may be waived under exceptional circumstances if a candidate shows evidence of other appropriate training and/or substantial research accomplishment.*

**THIS APPLICATION MUST INCLUDE:**

- 1) Three copies of your bibliography and curriculum vitae; 2) Three copies of a first author publication that meets the described criteria; 3) The name and signature of an active AAI member as your reference.

NAME: \_\_\_\_\_

TYPE OF DEGREE(S) AND DATE(S) RECEIVED: \_\_\_\_\_

INSTITUTION: \_\_\_\_\_

PUBLICATION: \_\_\_\_\_

CURRENT TITLE/ POSITION: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

STREET: \_\_\_\_\_

CITY: \_\_\_\_\_ STATE: \_\_\_\_\_ ZIP CODE: \_\_\_\_\_

COUNTRY \_\_\_\_\_ E-MAIL ADDRESS: \_\_\_\_\_

PHONE#: (\_\_\_\_\_) \_\_\_\_\_ FAX#: (\_\_\_\_\_) \_\_\_\_\_

RESEARCH SPECIALTY: \_\_\_\_\_

**REFERENCE:**NAME OF AAI MEMBER (*please print clearly*): \_\_\_\_\_

SIGNATURE OF AAI MEMBER: \_\_\_\_\_

Applications should be mailed to the AAI office and marked to the attention of the Chair of the AAI Membership Committee. Please **DO NOT** send payment with your application. You will be invoiced upon approval.

**Application Review Deadlines:**Applications are to be received in the AAI office by: **March 31** \* **June 30** \* **September 30** \* **December 31**2002 Dues Rates, 1 January - 31 December: **U.S. - \$225.00** \* **Canadian - \$323.00** \* **International - \$315.00**

## 2003 AAI-PHARMINGEN INVESTIGATOR AWARD

### DESCRIPTION

Since 1993, the AAI has presented the AAI-PharMingen Investigator Award to an early-career investigator who has made outstanding contributions to the field of immunology. This award was first called the "AAI Young Investigator Award" and retitled the "AAI Investigator Award" in 1995. In 1996, PharMingen became a co-sponsor of the award and the name was changed to reflect that partnership. In 1998, BD Biosciences became the parent company of PharMingen and co-sponsor of the award.

The award includes a plaque, a \$3,000 cash award, and travel support to attend the 2003 AAI Annual Meeting (May 6-10, 2003, in Denver, CO). The awardee is required to present his or her work at the AAI-PharMingen Investigator Award Ceremony and Lecture at the 2003 meeting.

### ELIGIBILITY

Nominees must be members in good standing with the AAI and must have received an advanced degree (Ph.D., M.D., or equivalent) within the last 15 years (hence, a 2003 nominee must have received his or her degree on or after June 1, 1988).

### NOMINATION

Individuals must be nominated by a regular AAI member in good standing. Members cannot nominate themselves. Members of the AAI Council and AAI Awards Committee are not eligible to nominate candidates, nor be nominated themselves. Nominees will be evaluated by the AAI Awards Committee, and recommendations will be made to the AAI Council for final selection. A complete nomination package must be received by **Monday, December 15, 2002**. Please address all nominations to:

M. Michele Hogan, Ph.D.  
Executive Director  
The American Association of Immunologists  
9650 Rockville Pike  
Bethesda, Maryland 20814

## AAI-PHARMINGEN INVESTIGATOR AWARD NOMINATION INSTRUCTIONS

Please include the following in the nomination package:

1. Name of nominee
2. Current mailing address (including email address)
3. Title and affiliation
4. Statement of contributions to immunology (*do not exceed 2 pages*)
5. CV including education and fellowships (institution, dates, degrees) and employment history
6. Bibliography (complete citations with titles; a reprint of **one** publication may be included)
7. A nomination letter submitted by an active AAI member
8. Two (2) letters of recommendation supporting this nomination must be submitted in addition to a signed nomination letter.

## 2003 AAI - HUANG FOUNDATION MERITORIOUS CAREER AWARD

### DESCRIPTION

This award, established by the AAI in 1999 in partnership with the Huang Foundation, is intended to recognize a mid-career scientist for outstanding research contributions he or she has made to the field of immunology.

The recipient will receive a \$10,000 cash award and travel support to attend the 2003 AAI Annual Meeting (May 6-10, 2003, in Denver, CO). The recipient will receive the award and present a lecture at the AAI-Huang Foundation Meritorious Career Award Ceremony and Lecture held at the 2003 meeting.

### ELIGIBILITY

This award competition is open to regular members of AAI who are at a mid-stage in their career. Applicants are to have at least 15 years' experience in the field (hence, the 2003 nominee must have received his or her degree on or before June 1, 1988). While an upper limit on career stage is not firmly set, this award is not intended for senior investigators.

### NOMINATION

Candidates must be nominated by a regular AAI member in good standing. Members cannot nominate themselves. Members of the AAI Council and AAI Awards Committee are not eligible to nominate candidates, nor be nominated themselves. Nominees will be evaluated by the AAI Awards Committee, and recommendations will be made to the AAI Council for final selection. A complete nomination package must be received by **Monday, December 15, 2002**. Please address all nominations to:

M. Michele Hogan, Ph.D.  
Executive Director  
The American Association of Immunologists  
9650 Rockville Pike  
Bethesda, Maryland 20814

## AAI - HUANG FOUNDATION MERITORIOUS CAREER AWARD NOMINATION INSTRUCTIONS

Please include the following in the nomination package:

1. Name of nominee
2. Current mailing address (including email address)
3. Title and affiliation
4. Statement of contributions to immunology (do not exceed 2 pages)
5. CV including education and fellowships (institution, dates, degrees) and employment history
6. Bibliography (complete citations with titles)
7. A nomination letter submitted by a regular AAI member in good standing
8. Two (2) letters of recommendation supporting this nomination must be submitted in addition to a signed nomination letter.

## 2003 AAI EXCELLENCE IN MENTORING AWARD

### DESCRIPTION

The Excellence in Mentoring Award was established by the AAI in 1995 to recognize the importance of the relationship between a mentor and trainee. A dedicated mentor can significantly influence the successful development and career of trainees. With this award, AAI honors a member for his or her contributions to the profession through outstanding mentoring.

The recipient will be recognized and receive the award at a ceremony during the 2003 AAI Annual Meeting (May 6-10, 2003, in Denver, CO).

### QUALIFICATIONS

Nominees must be regular members in good standing with the AAI who have demonstrated a commitment to mentoring throughout their career.

### NOMINATION

Candidates should be nominated by an AAI member in good standing who was mentored by the nominee and is well acquainted with the nominee's qualifications. AAI members cannot nominate themselves. Members of the AAI Council and AAI Awards Committee are not eligible to nominate candidates, nor be nominated themselves. The complete nomination package must be received by **Monday, December 15, 2002**. Please address all nominations to:

M. Michele Hogan, Ph.D.  
Executive Director  
The American Association of Immunologists  
9650 Rockville Pike  
Bethesda, Maryland 20814

## AAI EXCELLENCE IN MENTORING AWARD NOMINATION INSTRUCTIONS

Please include the following in the nomination package:

1. The nomination letter should include the following nominee information:

- Name
- Present title and affiliation
- Current mailing address (including email address)
- Succinct career history and major scientific contributions
- List of former and current trainees mentored by nominee, including names, position with mentor (e.g., post-doctoral fellow, student), dates of training, and the trainees' current positions

2. Letters of recommendation from up to four *former* trainees of the nominee. Each letter must include a brief description of career history relevant to mentoring received, as well as current positions and affiliations. Please use no more than two (2) pages to provide a narrative description of the guidance provided by the nominee.

Qualities that may be considered are the nominee's commitment to mentoring throughout his or her career; advising on career choices; willingness to advise trainees on activities critical to success within the scientific community, e.g., grant writing, manuscript preparation, oral presentations, teaching skills, etc.; continued interest in the professional advancement of former trainees; and success as a role model.



The American Association of Immunologists  
gratefully acknowledges  
**BD Biosciences**  
for its generous support of EB 2002

The following were made possible  
through unrestricted educational grants from  
**BD Biosciences:**

*EB 2002 Meeting Bags*  
*AAI Annual Gala*  
*AAI President's Reception*  
*AAI-Pharmingen Investigator Award and Lecture*

**BD Biosciences**

Clontech  
Discovery Labware  
Immunocytometry Systems  
Pharmingen



## WEB SITES OF INTEREST

*The AAI lists these web sites as a service to our membership and readership. AAI does not endorse or guarantee the information on the listed sites. If you wish to comment, or offer sites of interest, please contact AAI at [infoaai@aai.faseb.org](mailto:infoaai@aai.faseb.org).*

The High Wire Library of the Sciences and Medicine is a new web “portal” affording scientists one-stop access to the world’s largest and fastest growing archive of full-text biomedical research. The site currently contains access to nearly 12 million articles in some 4,500 Medline journals and over 430,000 free, full-text articles from the more than 300 journals HighWire produces on line. It also offers powerful new search, sort, and filter features and personalized, subject-specific email alerts. A visual browser allows users to search the site’s 22,000-topic taxonomy, developed in part by AAI. Visit <http://highwire.stanford.edu>.

*Secrets of the Sequence*, a weekly public television series launched in April, explores current discoveries in the life sciences. Hosted by Lucky Severson with the assistance of a talking e-book, *The Hitchhiker’s Guide to the Genome*, the program is “designed to bring viewers up to speed on the astounding discoveries emerging every day from laboratories around the world.” For information, including a list of upcoming programs and stations around the country which carry them, visit [http://www.wardtv.com/show\\_list.htm](http://www.wardtv.com/show_list.htm).

As the stem cell debate continues in earnest, a government report published last year remains an excellent source of context. *Stem Cells: Scientific Progress and Future Research Directions*, published by the Department of Health and Human Services (June 2001), explores the nature of stem cells and the promise of stem cell therapy in countering a variety of diseases that have long defied effective treatment. A downloadable copy of the report is available online at the NIH website -- visit <http://www.nih.gov/news/stemcell/scireport.htm>

---

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS  
9650 ROCKVILLE PIKE BETHESDA, MARYLAND 20814-3994

Non Profit Org.  
U.S. Postage  
PAID  
Bethesda, MD  
Permit 1126